ALLERGY/ASTHMA
PAA1 |
SUB-ACUTE LACK OF ASTHMA CONTROL AND SUBSEQUENT ACUTE ASTHMA EXACERBATIONS: EVIDENCE FROM MANAGED CARE DATA |
|
Klingman D1, Gutierrez B2, Burudpakdee C1, Wagner S2 |
|
1IMS Health, Falls Church, VA, USA, 2AstraZeneca, Wilmington, DE, USA |
| |
|
PAA2 |
PREVALENCE OF UNCONTROLLED SEVERE PERSISTENT ASTHMA PATIENTS IN PNEUMOLOGY AND ALLERGY HOSPITAL UNITS IN SPAIN |
|
Lahoz R1, Picado C2, Plaza V3, Quirce S4, Nadal T5, Casafont J1 |
|
1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Clínic i Provincial, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Hospital La Paz, Madrid, Spain, 5Trial Form Support, Barcelona, Spain |
| |
|
PAA3 |
A BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING A NEW EXTRAFINE COMBINATION (BECLOMETHASONE/FORMOTEROL) FOR THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SPAIN |
|
Darba J1, Restovic G2 |
|
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research, Barcelona, Spain |
| |
|
PAA4 |
COST-EFFECTIVENESS ANALYSIS OF OMALIZUMAB VS STANDARD THERAPY (ST), IN THE MANAGEMENT OF SEVERE ASHTMA |
|
Martínez M1, Vega G2, Garcia FM3, Rivas R2, Fon F1, Zapata L2 |
|
1Novartis, Mexico City, Mexico, 2Guia Mark, Mexico, DF, Mexico, 3IMSS, Mexico DF, Mexico |
| |
|
PAA5 |
CLINICO-ECONOMICAL ANALYSIS OF USING BUDESONID/FORMOTEROL INHALER FOR TREATMENT OF BRONCHIAL ASTHMA |
|
Vorobiev P, Avksentieva M, Smirnova M |
|
Moscow Medical Academy named after M.I.Sechenov, Moscow, Russia |
| |
|
PAA6 |
COST EFFECTIVENESS OF BREATH-OPERATED INHALERS IN UK PRIMARY CARE |
|
Haycox A1, Featherstone R2 |
|
1University of Liverpool Management School, Liverpool, UK, 2Knowledgeworks Ltd, Saffron Walden, UK |
| |
|
PAA7 |
A PHARMACOECONOMIC EVALUATION OF SUBLINGUAL IMMUNOTHERAPY COMPARED TO SUBCUTANEOUS IMMUNOTHERAPY IN THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS |
|
Kristensen FKO, Nyhus K, Merméjean P, Sverre JM |
|
PharmEcon, Asker, Akershus, Norway |
| |
|
PAA8 |
COST OF REFRACTORY SEVERE PERSISTENT ASTHMA IN CZECH REPUBLIC – COST OF ILLNESS STUDY |
|
Dolezal T1, Skoupá J2 |
|
1Charles University, Prague, Czech Republic, 2Pharma Projects, Prague, Czech Republic |
| |
|
PAA9 |
RISK-ADJUSTED COSTS AND OUTCOMES FOR MILD PERSISTENT ASTHMA PATIENTS ON ALTERNATIVE CONTROLLER THERAPIES |
|
Colice G1, Yu AP2, Ivanova JI2, Hsieh M2, Birnbaum HG2, Lage MJ3, Brewster C4 |
|
1Washington Hospital Center, Washington, DC, USA, 2Analysis Group, Inc, Boston, MA, USA, 3HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 4Teva Neuroscience/Teva Specialty Pharmaceuticals, Kansas City, MO, USA |
| |
|
PAA10 |
ADULT ASTHMA: A COHORT ANALYSIS OF USE AND COST OF HOSPITAL AND EMERGENCY DEPARTMENT CARE BY LOCATION OF RESIDENCE OVER TWELVE MONTHS |
|
O'Brien JA, Duran PA, Caro JJ |
|
Caro Research Institute, Concord, MA, USA |
| |
|
PAA11 |
ECONOMIC EVALUATION OF SECOND-LINE THERAPIES IN ADULT PATIENTS WITH ASTHMA WHEN CONSIDERING COMPLIANCE - AN ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE |
|
Pettersson B1, Soroncz-Szabo T2, Ekman M3, Taylor S4 |
|
1MSD, Sollentuna, Sweden, 2MSD Hungary Kft, Budapest, Hungary, 3Stockholm Health Economics, Stockholm, Sweden, 4Merck & Co., Inc, West Point, PA, USA |
| |
|
PAA12 |
EXTENT OF UNCONTROLLED DISEASE AND ASSOCIATED MEDICAL COSTS IN SEVERE ASTHMA IN THE NETHERLANDS |
|
Breekveldt-Postma NS1, Erkens JA1, Aalbers R2, van de Ven MJ3, Lammers JWJ4, Herings RM1 |
|
1PHARMO Institute, Utrecht, The Netherlands, 2Martini Hospital, Groningen, The Netherlands, 3Rijnstate Hospital, Arnhem, The Netherlands, 4University Medical Center Utrecht, Utrecht, The Netherlands |
| |
|
PAA13 |
THE MONTREAL PROTOCOL: CONCERNS OVER THE FUTURE TREATMENT OF ASTHMA |
|
Walters E1, Osborne M1, Ling C2, Johnson KI2 |
|
1Teva UK Ltd, Harlow, Essex, UK, 2Evidence Research Unit, Macclesfield, UK |
| |
|
PAA14 |
PHYSICIANS EDUCATIONAL EFFORTS: A TOOL FOR IMPROVING MANAGEMENT OF ASTHMA IN THE COMMUNITY |
|
Cohen R1, Triki N2, Kokia E3, Mossinson D1 |
|
1Maccabi Healthcare Services, Rishon-LeZion, Israel, 2Ben Guryon University of the Negev, Beer Sheva, Israel, 3Maccabi Healthcare Services, Tel-Aviv, Israel |
| |
|
PAA15 |
EFFECT OF IMMUNOTHERAPY ON DRUG USE AND COST IN RAGWEED POLLEN ALLERGIC DISEASE IN LOMBARDIA |
|
Ortolani C1, Berto P2, Frati F3, Aiello A2, Bertani G4 |
|
1Istituto Allergologico Lombardo OnLus, Cesano Boscone, Italy, 2pbe consulting, Verona, Italy, 3Stallergenes Italy, Milano, Italy, 4General Health Directorate - Regione Lombardia, Milano, Italy |
| |
|
PAA16 |
A RETROSPECTIVE STUDY COMPARING TREATMENT PATTERNS, OUTCOMES, AND RESOURCE USE BETWEEN TWO FIXED COMBINATIONS OF INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONIST (ICS/LABA) IN ASTHMATIC PATIENTS IN GERMANY |
|
Aballéa S1, Cure S1, Vogelmeier C2, Wirén A3 |
|
1i3 Innovus, Uxbridge, Middlesex, UK, 2University of Marburg, Marburg, Germany, 3AstraZeneca, Lund, Sweden |
| |
|
PAA17 |
PHYSICIAN ADHERENCE TO NATIONAL ASTHMA PRESCRIBING GUIDELINES: EVIDENCE FROM U.S. OUTPATIENT VISITS |
|
Navaratnam P1, Jayawant SS2, Pedersen CA2, Balkrishnan R2 |
|
1The Ohio State University, Columbus, OH, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA |
| |
|
PAA18 |
USING CLAIMS DATA TO MODEL THE BUDGETARY IMPACT OF A NEW TREATMENT FOR RHINITIS |
|
Pandya A1, Rubin JL1, Henk HJ2, Borah B2, McGarry L1 |
|
1i3 Innovus, Medford, MA, USA, 2i3 Innovus, Eden Prairie, MN, USA |
| |
|
PAA19 |
BI-MODALITY IN DISTRIBUTION OF MEDICATION POSSESSION RATIOS FOR ASTHMA CONTROLLER THERAPIES |
|
Langley P1, Wagner S2 |
|
1University of Minnesota, Minneapolis, MN, USA, 2AstraZeneca, Wilmington, DE, USA |
| |
|
PAA20 |
PHARMACOECONOMIC ANALYSIS OF A NEW CONCEPT FOR SYMBICORT USE IN BRONCHIAL ASTHMA PATIENTS |
|
Arkhipov VV, Chapurin S, Churilin Y |
|
Sechenov Moscow Medical Academy, Moscow, Russia |
| |
|
PAA21 |
DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL |
|
Soroncz-Szabo T1, Taylor SD2, Nagy L1, Sazonov Kocevar V2 |
|
1MSD Hungary Ltd, Budapest, Hungary, 2Merck & Co., Inc, Whitehouse Station, NJ, USA |
| |
|
PAA22 |
STATE TRANSITION MODELS FOR ESTIMATING TRANSITION PROBABILITIES IN MARKOV MODELS |
|
Campbell JD, Blough DK, Sullivan SD |
|
University of Washington, Seattle, WA, USA |
| |
|
PAA23 |
THE RELATIONSHIP BETWEEN QUALITY OF LIFE AND WILLINGNESS TO PAY IN PATIENTS WITH ASTHMA IN KOREA |
|
Park D1, Ko S2 |
|
1Seoul National University, Seoul, South Korea, 2Pfizer Korea, Seoul, South Korea |
|
|
CARDIOVASCULAR DISEASE
PCV1 |
AN OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF ROSUVASTATIN IN PATIENTS WITH DIABETES IN GENERAL PRACTICE ACROSS THE UK |
|
Kassianos G1, Reckless JP2, Emmas CE3, Evans M4, Tree A5, Vance A6 |
|
1Ringmead Medical Practice, Wokingham, Berkshire, UK, 2Royal United Hospital, Bath, UK, 3AstraZeneca UK, Luton, UK, 4Llandough Hospital, Penarth, UK, 5The Hollies Surgery, Liverpool, UK, 6Royton Health Centre, Oldham, UK |
| |
|
PCV2 |
EFFECTIVENESS OF MULTIPLE-MECHANISM ANTIHYPERTENSIVE MEDICATION: VALSARTAN-AMLODIPINE-HCTZ TRIPLE-THERAPY IN PRIMARY CARE |
|
Biskupiak J1, Brixner D1, Keskinaslan A2 |
|
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Novartis Pharma AG, Basel, Switzerland |
| |
|
PCV3 |
EFFECTIVENESS OF ROSUVASTATIN COMPARED TO OTHER STATINS FOR THE PREVENTION OF FATAL AND NON-FATAL CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE - AN EPIDEMIOLOGICAL STUDY |
|
Motsko SP1, Russmann S1, Ming EE2, Jones JK1 |
|
1The Degge Group, Ltd, Arlington, VA, USA, 2AstraZeneca LP, Wilmington, DE, USA |
| |
|
PCV4 |
META-ANALYSIS OF THE EFFICACY OF TELMISARTAN ON BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION |
|
Raikou M1, Theodoratou T2, Maniadakis N3 |
|
1London School of Economics and Political Science, London, UK, 2Boehringer Ingelheim Hellas, Elliniko, Greece, 3Medical Economics & Management Consultancy (MEM), Drosia, Greece |
| |
|
PCV5 |
EPROSARTAN VERSUS OTHER ANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND (IRBESARTAN, LOSARTAN, TELMISARTAN AND VALSARTAN) IN PATIENTS WITH HYPERTENSION-DIRECT ANALYSIS |
|
Wojcik R, Kaczor M, Walczak J, Nogas G |
|
Arcana Institute, Cracow, Poland |
| |
|
PCV6 |
ESTIMATING THE INCREMENTAL BENEFIT ON FINAL OUTCOMES OF ROSUVASTATIN 40MG OVER 20MG IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLAEMIA BASED ON A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS |
|
Kingslake SL, Edwards SJ |
|
AstraZeneca UK Ltd, Luton, UK |
| |
|
PCV7 |
DIFFERENCES IN CHOLESTEROL LEVELS BETWEEN STATIN AND FIBRATE TREATED PATIENTS IN FRENCH, ITALIAN AND UK PRIMARY CARE |
|
Blak BT1, Maguire A1, Schwalm MS2 |
|
1EPIC, London, UK, 2Cededim Strategic Data, Paris, France |
| |
|
PCV8 |
EPROSARTAN VERSUS OTHER ANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTS WITH HYPERTENSION-INDIRECT ANALYSIS |
|
Kaczor M, Wojcik R, Walczak J, Nogas G |
|
Arcana Institute, Cracow, Poland |
| |
|
PCV9 |
DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR CARDIOVASCULAR EVENTS AMONG 92035 USERS OF STATINS IN A REAL LIFE SETTING |
|
Heintjes EM1, Penning-van Beest FJA1, Johansson S2, Stalenhoef AF3, Herings RMC1 |
|
1PHARMO Institute, Utrecht, The Netherlands, 2AstraZeneca R&D, Mölndal, Sweden, 3Radboud University Medical Centre, Nijmegen, Gelderland, The Netherlands |
| |
|
PCV10 |
MULTIPLE REGRESSION ANALYSIS MODEL PREDICTED DIASTOLIC BLOOD PRESSURE |
|
Mekaroonreung S1, Auamnoy T1, Thaweechotepatara P1, Chantarastapornchit V2 |
|
1Chulalongkorn University, Bangkok, Thailand, 2Silpakorn University, Nakorn Pathom, Thailand |
| |
|
PCV11 |
ASSOCIATION AND CONTROL OF MAIN CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION SECTOR; A CROSS-SECTIONAL STUDY |
|
Sicras A1, Navarro R1, Velasco S1, Frías-Garrido X1, F Bobadilla J2 |
|
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain |
| |
|
PCV12 |
USING ADMINISTRATIVE DATA FOR QUALITY INDICATORS OF AMI HOSPITAL CARE IN HUNGARY |
|
Belicza É1, Takács E1, Boncz I2, Merkely B1 |
|
1Semmelweis University, Budapest, Hungary, 2University of Pécs, Pécs, Hungary |
| |
|
PCV13 |
RISK OF MAJOR BLEEDING DURING CONCOMITANT USE OF ANTIBIOTIC DRUGS AND COUMARIN ANTICOAGULANTS |
|
Koerselman J, Penning-van Beest FJ, Herings RM |
|
PHARMO Institute, Utrecht, Utrecht, The Netherlands |
| |
|
PCV14 |
CHARACTERIZATION, RISK FACTORS, CLINICAL OUTCOMES, AND ECONOMIC CONSEQUENCES OF BLEEDING ASSOCIATED WITH CARDIAC SURGERY: A SYSTEMATIC LITERATURE REVIEW |
|
Balu S1, Dutcher S2, Lee WC2, Joshi AV3, Bilde L4, Booth F3, Pashos CL1 |
|
1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc, Bethesda, MD, USA, 3Novo Nordisk Inc, Princeton, NJ, USA, 4Novo Nordisk A/S, Bagsværd, Denmark |
| |
|
PCV15 |
IMPACT OF CHANGES IN REIMBURSEMENT SYSTEM ON THE BUDGET FROM THE PAYER'S AND PATIENT'S PERSPECTIVE |
|
Skowron A |
|
Jagiellonian University, Cracow, Poland |
| |
|
PCV16 |
HEALTH INSURANCE COSTS OF STROKE HOSPITAL TREATMENTS IN HUNGARY; 2003 – 2005 |
|
Karpati K1, Boncz I2, Lindgren P3, Ekman M4, Brodszky V1, Majer I1, Bereczki D5, Gulacsi L1 |
|
1Corvinus University of Budapest, Budapest, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3i3/innovus, Stockholm, Sweden, 4Stockholm Health Economics, Stockholm, Sweden, 5University of Debrecen, Debrecen, Hungary |
| |
|
PCV17 |
METABOLIC CONTROL AND COSTS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK; A CROSS SECTIONAL ASSESSMENT OF A HEALTH MANAGEMENT ORGANIZATION DATABASE |
|
Sicras A1, F Bobadilla J2, Velasco S1, Navarro R1, Sánchez C2 |
|
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain |
| |
|
PCV18 |
ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF EXPLANTED ORGANS IN HEART TRANSPLANTATION |
|
Kalo Z |
|
Szeged University, Szeged, Hungary |
| |
|
PCV19 |
A MODEL-BASED ANALYSIS OF THE EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON DIRECT MEDICAL COSTS OF CORONARY HEART DISEASE EVENTS IN A SECONDARY PREVENTION POPULATION IN THE UNITED STATES |
|
Zhang B1, Friedman M1, Charland SL2, Burge RT2, Simko RJ2, Menzin J1 |
|
1Boston Health Economics, Inc, Waltham, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA |
| |
|
PCV20 |
EVALUATING GENDER DIFFERENCES IN HEALTHCARE RESOURCE USE AND OUTCOMES AMONG ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE |
|
Bharmal M1, Zyczynski T2, Linnstaedt A1, Kennedy L3, Gemmen EK1 |
|
1Quintiles Strategic Research & Safety, Falls Church, VA, USA, 2GE Healthcare, Princeton, NJ, USA, 3GE Healthcare, Buckinghamshire, UK |
| |
|
PCV21 |
COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN GREECE: THE ECON-APROS STUDY |
|
Kyriopoulos J1, Athanasakis K1, Zavras A2, Angeli A3, Geitona M4 |
|
1National School of Public Health, Athens, Greece, 2Harvard University, Boston, MA, USA, 3Sanofi-Aventis, Athens, Greece, 4University of Thessaly, Volos, Greece |
| |
|
PCV22 |
COST EFFECTIVENESS ANALYSIS OF BOSENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN SOUTH KOREA |
|
Lee TJ1, Kim J2, Sohn HS3, Kim D1 |
|
1Hallym University, Chuncheon, South Korea, 2Seoul National University, Seoul, South Korea, 3Sook Myung Women's University, Seoul, South Korea |
| |
|
PCV23 |
HOSPITAL COSTS FOR TREATMENT OF ACUTE HEART FAILURE: ECONOMIC ANALYSIS OF THE REVIVE II STUDY |
|
De Lissovoy G1, Fraeman K1, Mullahy J2, Durtschi A3, Sterz R4, Salon J5 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2University of Wisconsin, Madison, WI, USA, 3Abbott Laboratories, Powell, OH, USA, 4Abbott GmbH & Co. KG, Ludwigshafen, -, Germany, 5Abbott Laboratories, Columbus, OH, USA |
| |
|
PCV24 |
COST EFFECTIVENESS OF THE CARDIOVASCULAR PREVENTION WITH RAMIPRIL AND/OR STATINS IN HIGH RISK POPULATION IN ITALY |
|
Iannazzo S, Pradelli L |
|
Advanced Research Srl, Turin, Italy |
| |
|
PCV25 |
COST-EFFECTIVENESS OF PREHOSPITAL VERSUS INHOSPITAL THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION |
|
Teich VD1, Pavão ALB1, Vianna D2 |
|
1MedInsight Consulting, Rio de Janeiro, Brazil, 2University of Rio de Janeiro, Rio de Janeiro, Brazil |
| |
|
PCV26 |
COST-EFFECTIVENESS OF HIGH DOSE ATORVASTATIN COMPARED TO STANDARD DOSE PRAVASTATIN IN SECONDARY PREVENTION |
|
Borgman B |
|
Pfizer, Sollentuna, Sollentuna, Sweden |
| |
|
PCV27 |
ECONOMIC EVALUATION OF NEBIVOLOL COMPARED WITH PLACEBO IN ELDERLY PATIENTS WITH HEART FAILURE –A MODEL BASED ANALYSIS ALONGSIDE THE SENIORS TRIAL |
|
Yao G1, Freemantle N1, Flather M2, Tharmanathan P1, Coats A3, Poole-Wilson PA4 |
|
1University of Birmingham, Birmingham, UK, 2Royal Brompton and Harefield NHS Trust, London and Imperial College of Science Technology and Medicine, London, UK, 3University of Sydney, Sydney, Australia, 4Imperial College of Science Technology and Medicine, London, UK |
| |
|
PCV28 |
COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES AFTER HIP FRACTURE REPAIR (HFR) |
|
Raisch DW, Campbell HM, Taylor Z |
|
Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA |
| |
|
PCV29 |
THE COST-EFFECTIVENESS ANALYSIS OF CORONARY ARTERY DISEASE DIAGNOSTIC PARAMETERS IN A CLINICAL LABORATORY SETTING |
|
Bogavac-Satnojevic N1, Petrova Ivanova G2, Jelic-Ivanovic Z1, Memon L3, Spasic S1 |
|
1Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia, Serbia and Montenegro, 2Faculty of Pharmacy, Medical University, Sofia, Sofia, Bulgaria, Bulgaria, 3Clinical Chemistry Laboratory, Clinical Centre “Bežanijska kosa”, Belgrade, Serbia, Serbia and Montenegro |
| |
|
PCV30 |
COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION - A EUROPEAN MODEL BASED ON THE CLARITY AND COMMIT TRIALS: ADAPTATION TO HUNGARY |
|
Berg J1, Odhiambo R2, Lindgren P3 |
|
1Stockholm Health Economics, Stockholm, Sweden, 2sanofi-aventis Zrt, Budapest, Hungary, 3I3 innovus, Stockholm, Sweden |
| |
|
PCV31 |
LONG-TERM COST-EFFECTIVENESS OF RIMONABANT IN GERMANY |
|
Pirk O1, Hessel F2, Kotowa W1, Hertel N1 |
|
1IMS Health, Nuremberg, Germany, 2Sanofi-Aventis, Berlin, Germany |
| |
|
PCV32 |
COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION, TYPE-2 DIABETES AND RENAL DAMAGE IN MEXICO |
|
Hernandez H1, Lepe L2, Gonzalez A3, Lemus A4, Reyes A5 |
|
1National Medical Center, IMSS, Guadalajara, Jalisco, Mexico, 2National Medical Center, La Raza, Mexico City, D.F, Mexico, 3National Medical, Mexico City, D.F, Mexico, 4Sanofi aventis de México, Mexico City, D.F, Mexico, 5Mexican Children Hospital, Mexico City, D.F, Mexico |
| |
|
PCV33 |
RESOURCE USE AND TREATMENT COSTS FOR ACUTE DECOMPENSATED HEART FAILURE: ECONOMIC ANALYSIS OF THE SURVIVE TRIAL |
|
De Lissovoy G1, Fraeman K1, Sterz R2, Salon J3 |
|
1United BioSource Corporation, Bethesda, MD, USA, 2Abbott GmbH & Co. KG, Ludwigshafen, Germany, 3Abbott Laboratories, Columbus, OH, USA |
| |
|
PCV34 |
COST-EFFECTIVENESS OF ATORVASTATIN PLUS AMLODIPINE VERSUS ATORVASTATIN PLUS ATENOLOL IN HYPERTENSIVE PATIENTS WITHOUT PREVIOUS CORONARY HEART DISEASE, NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS AND AT LEAST 3 CARDIOVASCULAR RISK FACTORS |
|
F Bobadilla J1, Merikle E2, García M3, Darba J4, Sánchez C1 |
|
1Pfizer Spain, Madrid, Spain, 2Pfizer Canada, Kirkland, ON, Canada, 3Euroclin Institute, Madrid, Spain, 4Universitat de Barcelona, Barcelona, Spain |
| |
|
PCV35 |
USE OF DRUG-ELUTING STENTS IN THE THERAPY AND PREVENTION OF RESTENOSIS: AN ECONOMIC EVALUATION FOR THE SICILY REGIONAL GOVERNMENT IN ITALY |
|
Colombo GL, Di Matteo S, Vinci M |
|
S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy |
| |
|
PCV36 |
COST-EFFECTIVENESS OF THE MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA WITH A PREVENTIVE TREATMENT ATORVASTATIN-BASED |
|
F Bobadilla J1, Mata P2, Méndez I3, Alonso R2, Sánchez Maestre C1 |
|
1Pfizer Spain, Madrid, Spain, 2Fundación Jiménez Díaz, Madrid, Spain, 3Técnicas Avanzadas de Investigación en Servicios de Salud (TAISS), Madrid, Spain |
| |
|
PCV37 |
COST-EFFECTIVENESS OF ATORVASTATIN, ROSUVASTATIN, AND SIMVASTATIN IN REDUCING LDL-CHOLESTEROL TO MEET THE EUROPEAN TARGET LEVEL – BAYESIAN META-ANALYSIS AND SIMULATION |
|
Peura P1, Martikainen JA1, Hallinen T1, Soini EJ1, Niskanen L2 |
|
1University of Kuopio, Kuopio, Finland, 2Kuopio University Hospital, Kuopio, Finland |
| |
|
PCV38 |
COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION: A COMPARATIVE ANALYSIS USING CLINICAL TRIAL AND OBSERVATIONAL DATA |
|
Boersma C1, Voors AA2, Van den Berg PB1, Visser ST1, De Jong-van den Berg LT1, Postma MJ1 |
|
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands |
| |
|
PCV39 |
COST UTILITY ANALYSIS OF CLOPIDOGREL IN ADDITION TO STANDARD CARE FOR ST-ELEVATED MYOCARDIAL INFARCTION: THE UK PERSPECTIVE |
|
Holmes M |
|
University of Sheffield, Sheffield, South Yorkshire, UK |
| |
|
PCV40 |
STUDY OF THE COST OF OUTPATIENT HYPERTENSION THERAPY IN BULGARIA |
|
Petrova GI, Ivanova AD |
|
Medical University, Faculty of Pharmacy, Sofia, Bulgaria |
| |
|
PCV41 |
COSTS AND LENGTH OF STAY IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE |
|
Ondrackova B1, Miklik R2, Parenica J2, Spinar J2, Sticha M1 |
|
1Masaryk University, Brno, Czech Republic, 2Faculty Hospital Brno, Brno, Czech Republic |
| |
|
PCV42 |
ANTICOAGULATION CONTROL IN DIFFERENT SETTINGS OF CARE: PERCEPTION, DIRECT NON-HEALTH CARE COSTS AND PRODUCTIVITY LOSSES AMONGST PATIENTS WITH ATRIAL FIBRILLATION IN AN ITALIAN REGION. |
|
Aguzzi G1, Fattore G1, Falcone A2, Agnelli G3 |
|
1Bocconi University, Milan, Italy, 2AstraZeneca Italia, Basiglio, Italy, 3Perugia University, Perugia, Italy |
| |
|
PCV43 |
DIRECT COSTS ASSOCIATED WITH THE POTENTIAL COMPLICATIONS OF INCREASED CARDIOMETABOLIC RISK STATES |
|
Nagy J1, Borsos K2, Belicza É3, Skultéty L1, Vandorfi G4, Nagy B1 |
|
1GKI-EKI Healthcare Research Institute Ltd, Budapest, Hungary, 2sanofi-aventis Zrt, Budapest, Hungary, 3Semmelweis University, EMK, Budapest, Hungary, 4Csolnoky Ferenc Hospital, Veszprem County, Veszprém, Hungary |
| |
|
PCV44 |
COST-EFFECTIVENESS ANALYSIS OF THE USE OF VISIPAQUE COMPARED TO OMNIPAQUE IN THE UK (UK) |
|
Zyczynski T1, Beard S2, Earnshaw SR3, McDade CL3 |
|
1GE Healthcare, Princeton, NJ, USA, 2RTI Health Solutions, Manchester, Greater Manchest, UK, 3RTI Health Solutions, Research Triangle Park, NC, USA |
| |
|
PCV45 |
COST-UTILITY ANALYSIS OF RIMONABANT IN THE MANAGEMENT OF OBESITY/OVERWEIGHT PATIENTS WITH CARDIOMETABOLIC RISK FACTORS IN HUNGARY |
|
Nagy B1, Borsos K2, Blaskó G3 |
|
1GKI-EKI Healthcare Research Institute Ltd, Budapest, Hungary, 2sanofi-aventis Zrt, Budapest, Hungary, 3University of Debrecen, Debrecen, Hungary |
| |
|
PCV46 |
ECONOMIC EVALUATION OF 80 MG ATORVASTATIN COMPARED TO 20-40 MG SIMVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES |
|
Lindgren P1, Olsson AG2, Pedersen T3, Jönsson B4 |
|
1I3 innovus, Stockholm, Sweden, 2Linköping University Hospital, Linköping, Sweden, 3Ullvål University Hospital, Oslo, Norway, 4Stockholm School of Economics, Stockholm, Sweden |
| |
|
PCV47 |
COST-EFFECTIVENESS OF ENDOVASCULAR REPAIR (EVAR) COMPARED WITH OPEN SURGERY REPAIR (OSR) FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSM (AAA) IN ITALY |
|
Colombo GL1, Gabrielli L2, Inglese L3, Mazzei L4, Palmieri B5, Puttini M5, Brasseur P6 |
|
1SAVE Studi Analisi Valutazioni Economiche, Milan, Italy, 2Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy, 3IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy, 4Assobiomedica, Milan, Italy, 5Azienda Ospedaliera Niguarda Cà Granda, Milan, Italy, 6Medtronic International SA, Tolochenaz, Switzerland |
| |
|
PCV48 |
MAJOR BLEED RESOURCE USE AND COSTS FOR PATIENTS HOSPITALISED WITH ACUTE CORONARY SYNDROME IN FRANCE, ITALY AND SPAIN |
|
Brown R1, Parnaby A2, Guijarro P3, Nachit-Ouinekh F2, Bamfi F4 |
|
1United BioSource Corporation, London, UK, 2GlaxoSmithKline, Paris, France, 3GlaxoSmithKline, Madrid, Spain, 4GlaxoSmithKline Spa, Verona, Veneto, Italy |
| |
|
PCV49 |
BUDGET IMPACT AND MEDICAL RESOURCES USED TO CONTROL BLEEDS IN PATIENTS HOSPITALIZED DUE TO ACUTE CORONARY SYNDROME (ACS) |
|
Guijarro P1, Marimón F2, Guindo J3, Coves FJ4, Sionis A5, Pedrós M6, Layola M6 |
|
1GlaxoSmithKline, Madrid, Spain, 2Hospital San Joan, Reus (Tarragona), Spain, 3Hospital Santa Creu i Sant Pau, Barcelona, Spain, 4Hospital Gral. Univ. De Elche, Elche (Alicante), Spain, 5Hospital Clinic I Provincial, Barcelona, Spain, 6IMS Health, Barcelona, Spain |
| |
|
PCV50 |
COSTS OF MAJOR BLEEDS IN ACUTE CORONARY SYNDROME PATIENTS |
|
Brown R1, Ferrari E2, Drogoul L2, Nachit-Ouinekh F3, De Cock E4 |
|
1United BioSource Corporation, London, London, UK, 2Hopital Pasteur, Nice, France, 3GlaxoSmithKline, Paris, France, 4United BioSource Corporation, Barcelona, Spain |
| |
|
PCV51 |
ESTIMATING THE IMPACT OF MANDATORY SWITCH FROM ATORVASTATIN TO SIMVASTATIN IN NORWAY |
|
Høeg AL1, Lones O1, Roberts CS2, Graham LA3 |
|
1Pfizer AS, Lysaker, Norway, 2Pfizer Inc, New York, NY, USA, 3Pfizer Ltd, Tadworth, Surrey, UK |
| |
|
PCV52 |
ATTITUDES AND BELIEFS OF PHYSICIANS ABOUT HYPERCHOLESTEROLEMIA IN SPAIN: THE PRACTICE STUDY |
|
Nocea G1, Troya J2, Garcia E3, Gimenez G4, Marcos G5, Caloto MT6, Alemao E7, Suarez C8 |
|
1MSD Spain, Madrid, Spain, 2H. Virgen de la Salud, Toledo, Spain, 3Consultorio El Carpio, Cordoba, Spain, 4H. Parc Tauli, Barcelona, Spain, 5H. San Pedro de Alcantara, Caceres, Spain, 6Merck, Sharp & Dohme, Madrid, Spain, 7Merck & Co, Whitehouse Station, NJ, USA, 8H. de La Princesa, Madrid, Spain |
| |
|
PCV53 |
STATIN USE AMONG PATIENTS WITH CONFIRMED CORONARY ARTERY DISEASE (CAD) OR RELATED RISK FACTORS: A COMPARISON BETWEEN EUROPE & THE UNITED STATES (US) |
|
Narayanan S1, Turner G2, Mitchell A2, Chadwell P2, O'Hagan P2 |
|
1TNS Healthcare, Stamford, CT, USA, 2TNS UK Ltd, Epsom, Surrey, UK |
| |
|
PCV54 |
ATTAINMENT OF LDL CHOLESTEROL GOALS AMONG HIGH RISK PATIENTS WITH CARDIOVASCULAR DISEASE (CVD): HOW LARGE WAS THE GAP BETWEEN EUROPE & THE UNITED STATES (US) IN 2006? |
|
Narayanan S1, Turner G2, Mitchell A2, Chadwell P2, O'Hagan P2 |
|
1TNS Healthcare, Stamford, CT, USA, 2TNS UK Ltd, Epsom, Surrey, UK |
| |
|
PCV55 |
LIPID LOWERING AGENTS CONSUMPTION AND COSTS IN THE SLOVAK REPUBLIC |
|
Oleárová A, Foltán V, Majtás J |
|
Comenius University, Bratislava, Slovak Republic |
| |
|
PCV56 |
STATIN PRESCRIPTION PATTERNS IN A LOCAL HEALTH UNIT: A FIVE-YEAR-ANALYSIS |
|
Lopatriello S1, Salvato C2, Maccari D2, Negrini C3 |
|
1pbe consulting, Verona, Italy, 2ASL 7 Pieve di Soligo (TV), Pieve di Soligo, Italy, 3PBE Consulting, Milano, Italy |
| |
|
PCV57 |
UTILISATION OF DRUGS FOR TREATMENT OF CARDIOVASCULAR DISEASE WITHIN SLOVAKIA |
|
Tesar T1, Foltan V1, Tomek D2, Ilavska A3 |
|
1Comenius University, Bratislava, Slovak Republic, 2Health Insurance Fund Apollo, Bratislava, Slovak Republic, 3Railway Hospital, Bratislava, Slovak Republic |
| |
|
PCV58 |
COMPARISON OF REASONS BEHIND PHYSICIANS' ANTIHYPERTENSIVE THERAPY CHOICE IN THE UNITED STATES (US) AND EUROPE |
|
Narayanan S1, Turner G2, Mitchell A2, Chadwell P2, O'Hagan P2 |
|
1TNS Healthcare, Stamford, CT, USA, 2TNS UK Ltd, Epsom, Surrey, UK |
| |
|
PCV59 |
ASSESSMENT OF THE USE OF ANGIOTENSIN RECEPTOR BLOCKERS IN THE EUROPEAN UNION PEDIATRIC POPULATION FOR TREATING ESSENTIAL HYPERTENSION |
|
Phatak HM1, Vogelsang E1, Gleim GW2, Smith RD1, Loran B2 |
|
1Merck & Co., Inc, Whitehouse Station, NJ, USA, 2Merck Research Laboratories, Rahway, NJ, USA |
| |
|
PCV60 |
VARIATION OF OUTLIER PAYMENTS AMONG HOSPITALS |
|
Baser O |
|
University of Michigan and STATinMED Research, Ann Arbor, MI, USA |
| |
|
PCV61 |
INDICATOR OF CARDIOVASCULAR MEDICINES USAGE IN PUBLIC PHARMACY CHAIN BELGRADE |
|
Sovtic D, Dekic S, Opacina I |
|
Pharmacy "Belgrade", Belgrade, Serbia and Montenegro |
| |
|
PCV62 |
PRIVATE PAYER EPISODE COSTS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY VS. MYOCARDIAL PERFUSION IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE |
|
Min J1, Gilmore A2, Legorreta AP3, Robinson M2 |
|
1Weill Medical Coll of Cornell Univ, New York, NY, USA, 2Health Benchmarks, Inc, Woodland Hills, CA, USA, 3UCLA School of Public Health, Woodland Hills, CA, USA |
| |
|
PCV63 |
WITHDRAWN |
|
|
|
|
| |
|
PCV64 |
CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG-A SINGLE CETRE "REAL WORLD" EXPERIENCE: AN INTERIM ANALYSIS |
|
Lee VWY, Kum L, Lee T, Wong W, Yu C |
|
The Chinese University of Hong Kong, Shatin, Hong Kong |
| |
|
PCV65 |
LIKELIHOOD OF INITIATING ANTILIPIDEMICS BY PATIENT SEX, RACE/ETHNICITY, AGE, AND COMORBIDITY: LARGE-SCALE ANALYSIS OF FLORIDA MEDICAID-ENROLLED ADULTS WITH NEWLY DIAGNOSED DYSLIPIDEMIA |
|
Hankin C1, Fish L2, Dunn JD3, Fenrick R4, Bronstone A1, Wang Z1 |
|
1BioMedEcon, Moss Beach, CA, USA, 2Fallon HealthCare System, Worchester, MA, USA, 3SelectHealth Plans, Salt Lake City, UT, USA, 4Blue Cross Blue Shield of Florida, Jacksonville, FL, USA |
| |
|
PCV66 |
WITHDRAWN |
|
|
|
|
| |
|
PCV67 |
MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION (STEMI) ACCORDING TO GUIDELINES IN SPAIN |
|
Galera J1, Franca R1, Puig X1, Bardají A2 |
|
1Novartis Farmacéutica S.A, Barcelona, Spain, 2Hospital Universitari Joan XXIII, Tarragona, Spain |
| |
|
PCV68 |
CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS) |
|
Hermans MP1, Castro Cabezas M2, Strandberg T3, Moses E4, Sansoy V5, Aires N6, Ditmarsch M6 |
|
1Cliniques universitaires St-Luc, Brussels, Belgium, 2Sint Franciscus Gasthuis, Rotterdam, The Netherlands, 3University of Oulu, Oulu, Finland, 4University of Ioannina, Ioannina, Greece, 5Istanbul University, Istanbul, Turkey, 6AstraZeneca, Mölndal, Sweden |
| |
|
PCV69 |
SIMPLE SENSITIVITY ANALYSIS TO ASSESS THE IMPACT OF ROUNDING OF BLOOD PRESSURE MEASUREMENTS ON ESTIMATES OF CONTROL RATES |
|
Ishak KJ1, Payne K1, Caro JJ2, Khan ZM3, Daley WM3, Califf R4 |
|
1Caro Research Institute, Montreal, QC, Canada, 2Caro Research Institute, Concord, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Duke Clinical Research Institute, Durham, NC, USA |
| |
|
PCV70 |
MULTINOMIAL PROPENSITY SCORE ESTIMATORS AND MULTIVARIATE EXPLANATORY TECHNIQUES IN A REAL-LIFE ACUTE CORONARY HEART DISEASE STUDY – THE QALYS AND COSTS OF MEDICATION, PTCA AND CABG TREATMENT MODALITY ARE HIGHLY DEPENDENT ON THE METHODS USED |
|
Soini EJ |
|
ESiOR Ltd, Kuopio, Finland |
| |
|
PCV71 |
AN EVALUATION OF STATIN PERFORMANCE: A BIVARIATE AND TRIVARIATE SELECTION RULE APPROACH |
|
Livengood K |
|
University of Southern California, Los Angeles, CA, USA |
| |
|
PCV72 |
EMPIRICAL EVALUATION OF THE PREDICTIVE PERFORMANCE OF CLASSIFICATION TOOLS IN CORONARY HEART DISEASE – P-COURSE, A NAIVE BAYES TOOL, OUTPERFORMS NOVEL LOGISTIC REGRESSION APPROACHES |
|
Blomstedt P1, Soini EJ2, Lahtinen J3, Ryynänen OP4, Kuukasjärvi P5, Corander J1 |
|
1University of Helsinki, Helsinki, Finland, 2Equal contribution of both first authors. CEPPE and Department of Health Policy and Management, University of Kuopio, Kuopio, Finland, 3Complex Systems Computation Research Group (CoSCo), Helsinki Institute for Information Technology (HIIT), University of Helsinki, Helsinki, Finland, 4University of Kuopio, Kuopio, Finland, 5Finnish Office for Health Technology Assessment (FinOHTA), Helsinki, Finland |
| |
|
PCV73 |
A TOOL FOR MODELING MORTALITY DIFFERENCES IN PREDICTIVE SCREENING MODELS |
|
Stollenwerk B, Siebert U |
|
UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i. T, Austria |
| |
|
PCV74 |
A COMPARATIVE PHARMACOECONOMIC ANALYSIS OF STATINS IN RUSSIA |
|
Rudakova AV1, Miller PSJ2 |
|
1Military Medical Academy, St-Petersburg, Russia, 2AstraZeneca, Alderley Park, UK |
| |
|
PCV75 |
THE ANALYSIS OF HEALTH AND ECONOMIC BENEFITS AS THE CONSEQUENCE OF THE REALIZATION CARDIOVASCULAR SYSTEM DISEASES PREVENTION PROGRAMME AMONG THE CHILDREN AND YOUTH OF SCHOOL AGE IN POLAND |
|
Maciejewski J, Sinkiewicz W |
|
Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Kujawsko-pomorsk, Poland |
| |
|
PCV76 |
MEASUREMENT OF FRACTIONAL FLOW RESERVE IN PATIENTS WITH CORONARY ARTERY DISEASE TO GUIDE TREATMENT - RESULTS FROM A HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYTIC MODEL |
|
Siebert U1, Bornschein B2, Schnell-Inderst P3, Rieber J4, Pijls N5, Wasem J3, Klauss V4 |
|
1UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i. T, Austria, 2UMIT University of Health Sciences, Medical Informatics, and Technology, Hall i. T, Austria, 3University of Duisburg-Essen, Essen, Germany, 4University of Munich, Munich, Germany, 5Catharina Hospital Eindhoven and Eindhoven University of Technology, Eindhoven, The Netherlands |
| |
|
PCV77 |
RESPONSE-SHIFT IN HEART DISEASE: COMPARING INDIVIDUALIZED VS. DISEASE-SPECIFIC HRQL INSTRUMENTS |
|
Höfer S, Pfaffenberger N, Renn D, Platter M |
|
Medical University Innsbruck, Innsbruck, Austria |
| |
|
PCV78 |
MONITORING AND ASSESSING ADHERENCE TO STATINS THERAPY IN REAL PRACTICE USING ADMINISTRATIVE DATABASES |
|
Vagnoni E1, Degli Esposti L1, Mazzanti B2, Fresca G2, Falcone A3 |
|
1University of Ferrara, Ferrara, Italy, 2Local Health Unit of Ferrara, Ferrara, Italy, 3AstraZeneca, Basiglio, MI, Italy |
| |
|
PCV79 |
PERSISTENCE TO ANTILIPIDEMICS VARIES BY SEX, AGE, AND RACE/ETHNICITY: ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE |
|
Hankin C1, Dunn JD2, Fenrick R3, Fish L4, Wang Z1, Bronstone A1 |
|
1BioMedEcon, Moss Beach, CA, USA, 2SelectHealth Plans, Salt Lake City, UT, USA, 3Blue Cross Blue Shield of Florida, Jacksonville, FL, USA, 4Fallon HealthCare System, Worchester, MA, USA |
| |
|
PCV80 |
PERSISTENCE AND ADHERENCE TO HYPOLIPEMIC THERAPY IN REAL PRACTICE: RESULTS OF A LARGE ADMINISTRATIVE DATABASE |
|
Mantovani LG1, Fornari C2, Madotto F2, Chiodini V2, Veronesi G3, Ferrario M3, Cesana G2 |
|
1University of Naples, Federico II, Naples, Italy, 2University of Milano-Bicocca, Monza, Lombardia, Italy, 3University of Insubria, Varese, Lombardia, Italy |
| |
|
PCV81 |
WITHDRAWN |
| |
|
PCV82 |
FACTORS INFLUENCING COMPLIANCE WITH COMBINATION ANTIHYPERTENSIVE PHARMACOTHERAPY IN A LARGE US DATABASE |
|
Brixner D1, Jackson KC2, Oberg B2, Keskinaslan A3, Sheng X2 |
|
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2University of Utah Health Sciences Center, Salt Lake City, UT, USA, 3Novartis Pharma AG, Basel, Switzerland |
| |
|
PCV83 |
ADHERENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT: EVIDENCE FROM PRIMARY CARE PRACTICE IN ITALY |
|
Degli Esposti L1, Cerra C2, Veronesi C1, Buda S1 |
|
1Clicon s.r.l, Ravenna, Italy, 2Azienda Sanitaria Locale di Pavia, Pavia, Italy |
| |
|
PCV84 |
WHAT FACTORS AFFECT COMPLIANCE OF HYPERTENSIVE PATIENTS WITH THEIR TREATMENT? A QUALITATIVE STUDY |
|
Jin J1, Sklar GE1, Oh MS2, Li SC3 |
|
1National University of Singapore, Singapore, Singapore, 2National University Hospital, Singapore, Singapore, 3University of Newcastle, Callaghan, NSW, Australia |
| |
|
PCV85 |
DOES A SINGLE PILL COMBINING AMLODIPINE AND ATORVASTATIN OFFER GREATER LONG-TERM ADHERENCE BENEFIT OVER LOW-COST GENERIC 2-PILL CALCIUM CHANNEL BLOCKER/STATIN REGIMENS? |
|
Patel BV1, Tang SSK2, Leslie RS1, Nichol MB3, Solomon HA2, Trainer JB2, Foody JM4 |
|
1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Pfizer Inc, New York, NY, USA, 3University of Southern California, Los Angeles, CA, USA, 4Yale University, New Haven, CT, USA |
| |
|
PCV86 |
THE IMPACT OF LOWERING SYSTOLIC BLOOD PRESSURE ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS IN GREECE: THE ECON-APROS STUDY |
|
Geitona M1, Athanasakis K2, Angeli A3, Hatzakis A4, Kyriopoulos J2 |
|
1University of Thessaly, Volos, Greece, 2National School of Public Health, Athens, Greece, 3Sanofi-Aventis, Athens, Greece, 4University of Athens, Medical School, Athens, Greece |
| |
|
PCV87 |
WITHDRAWN |
| |
|
PCV88 |
QUALITY OF LIFE AS A PREDICTOR OF TREATMENT COMPLIANCE DURING ROUTINE HYPERTENSION MANAGEMENT: RESULTS OF PROSPECTIVE EVALUATION |
|
Mily MN |
|
Vitebsk State Medical University, Vitebsk, Belarus |
| |
|
PCV89 |
THE IMPACT OF COMMUNITY HEALTH WORKER INTERVENTION ON DISEASE MANAGEMENT AND QUALITY OF LIFE OF HIGH RISK POPULATION WITH CHRONIC DISEASE: EXPERIENCE IN BALTIMORE, MD, USA |
|
Fedder DO1, Fan T2, Curry S1 |
|
1University of Maryland, Baltimore, Baltimore, MD, USA, 2Merck & Co., Inc, Whitehouse Station, NJ, USA |
| |
|
PCV90 |
INTEGRATION OF PATIENT-RATED OUTCOMES INTO CLINICAL ROUTINE IN INPATIENT AND OUTPATIENT CARDIAC REHABILITATION PROGRAMMES |
|
Höfer S1, Benzer W2, Philippi A3, Mayr K4, Laimer H5, Hutter I5, Graninger U6, Müller R6 |
|
1Medical University Innsbruck, Innsbruck, Austria, 2Academic Hospital Feldkirch, Feldkirch, Austria, 3Reha-Sports-Institute, Feldkirch, Austria, 4Centre for Lifestyle Medicine, Linz, Austria, 5Cardiac Rehabilitation Centre, Bad Tatzmannsdorf, Austria, 6Pensionsversicherungsanstalt, Vienna, Austria |
| |
|
PCV91 |
HEALTH OUTCOMES IN PATIENTS WITH HYPERTENSION: WHAT HAVE WE IMPROVED IN TEN YEARS? |
|
Garcia AJ1, Leiva F2, Aguiar C2, Artacho R2, Vidal F2, Barnestein P2 |
|
1Universidad de Malaga, Malaga, Spain, 2Servicio Andaluz De Salud, Malaga, Spain |
| |
|
PCV92 |
ATTITUDES AND BELIEFS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK, ABOUT HYPERCHOLESTEROLEMIA AND ITS TREATMENT IN SPAIN. THE PRACTICE STUDY |
|
Caloto MT1, Troya J2, Garcia E3, Gimenez G4, Marcos G5, Nocea G6, Alemao E7, Suarez C8 |
|
1Merck, Sharp & Dohme, Madrid, Spain, 2H. Virgen de la Salud, Toledo, Spain, 3Consultorio El Carpio, Cordoba, Spain, 4H. Parc Tauli, Barcelona, Spain, 5H. San Pedro de Alcantara, Caceres, Spain, 6MSD Spain, Madrid, Spain, 7Merck & Co, Whitehouse Station, NJ, USA, 8H. de La Princesa, Madrid, Spain |
| |
|
PCV93 |
THE EFFECT OF EACH STAGE IN THE TRANSLATION METHODOLOGY FOR PRO MEASURES |
|
Gordon-Stables R, Wild D |
|
Oxford Outcomes Ltd, Oxford, UK |
| |
|
PCV94 |
EFFECTS OF COMORBID CONDITIONS AMONG THE OVERWEIGHT/OBESE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT |
|
Kannan H1, Thompson S2, Bolge SC1 |
|
1Consumer Health Sciences, Princeton, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA |
|
|
INFECTION
PIN1 |
SYSTEMATIC REVIEW OF THE SAFETY OF ANTIRETROVIRAL THERAPIES FOR REDUCING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION |
|
Suksomboon N1, Poolsup N2, Ket-aim S1 |
|
1Mahidol University, Bangkok, Thailand, 2Silpakorn University, Nakhon-Pathom, Thailand |
| |
|
PIN2 |
THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS OF INFLUENZA VACCINATION REIMBURSEMENT IN CHILDREN WITH MALIGNANCIES IN POLAND |
|
Dardzinski W, Wojcik R, Walczak J, Nogas G |
|
Arcana Institute, Cracow, Poland |
| |
|
PIN3 |
A WORKSITE INFLUENZA VACCINATION PROGRAM IN RUSSIA: A COST-BENEFIT ANALYSIS |
|
Atkov O1, Loguinov A2, Nicoloyannis N3, Durand L4 |
|
1Joint Stock Company Russian Railways (OAO RZHD), Moscow, Russia, 2Sanofi Pasteur, Moscow, Russia, 3University Lumière Lyon 2, Bron cedex, France, 4Sanofi Pasteur, Lyon cedex 07, France |
| |
|
PIN4 |
COST-BENEFIT ANALYSIS OF OSELTAMIVIR VERSUS NO ANTIVIRAL TREATMENT FROM THE EMPLOYER PERSPECTIVE: THE ROCHE BRAZIL CASE |
|
Moreno AC1, Saggia MG2, Santos EA2, Rodrigues S2 |
|
1Health Secretary of Sao Paulo City, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PIN5 |
COST-EFFECTIVENESS OF TIGECYLINE IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN GERMANY |
|
Kuchenbecker U1, Runge C1, Krueger WA2 |
|
1Wyeth Pharma, Muenster, Germany, 2Eberhard-Karls-University, Tuebingen, Germany |
| |
|
PIN6 |
EPIDEMIOLOGIC AND ECONOMIC IMPACT OF ROUTINE VACCINATION OF INFANTS AGAINST ROTAVIRUS GASTROENTERITIS IN GERMANY: A PRELIMINARY ANALYSIS |
|
Hammerschmidt T1, Forster J2, Huppertz HI3, Heininger U4, Roos R5, Standaert BA6 |
|
1GlaxoSmithKline, Munich, Germany, 2St. Josefs-Hospital, Freiburg, Germany, 3Prof.-Hess Children’s Hospital, Bremen, Germany, 4University-Children’s Hospital Basel, Basle, Switzerland, 5Hospital Munich-Harlaching, Munich, Germany, 6GlaxoSmithKline Biologicals, Rixensart, Belgium |
| |
|
PIN7 |
BURDEN OF PAEDIATRIC ROTAVIRUS GASTROENTERITIS AND POTENTIAL BENEFITS OF A UNIVERSAL VACCINATION PROGRAMME IN GERMANY |
|
Buesch K1, Ezzat N2, Trichard M3, Largeron N3 |
|
1Sanofi Pasteur MSD, Leimen, Germany, 2Alpha Care GmbH, Celle, Germany, 3sanofi pasteur MSD, Lyon, France |
| |
|
PIN8 |
COST EFFECTIVENESS OF THE MF59-ADJUVANTED INFLUENZA VACCINE IN FRANCE: THE "AT-RISK" ADULT POPULATION |
|
Chambers J1, Tolley K2, Piercy J3, Wait S4 |
|
1Mapi Values Ltd, Macclesfield, Cheshire, UK, 2Mapi Values, Bollington, Cheshire, UK, 3Adelphi Group, Bollington, UK, 4SHW Health, London, UK |
| |
|
PIN9 |
A COST-EFFECTIVENESS ANALYSIS OF A YEARLY FIBROSCAN® LIVER FIBROSIS ASSESSMENT COMPARED WITH A PERIODIC LIVER BIOPSY IN HEPATITIS C VIRUS (HCV) INFECTED INDIVIDUALS IN A FRENCH SETTING |
|
Levesque K1, De Lédinghen V2, Bourlière M3, Miadi-Fargier H1, Billon S1, LePen C4 |
|
1AREMIS Consultants, Neuilly-sur-Seine, France, 2Haut-Lévêque Hospital, Pessac, France, 3Saint Joseph Hospital, Marseille, France, 4Paris Dauphine University, Paris, France |
| |
|
PIN10 |
COST-EFFECTIVENESS OF DIFFERENT PERTUSSIS VACCINATION STRATEGIES FOR THE PROTECTION OF YOUNG INFANTS |
|
Westra TA1, Postma MJ1, Tamminga HJ2, De Vries R1 |
|
1University of Groningen, Groningen, The Netherlands, 2GlaxoSmithKline, Zeist, The Netherlands |
| |
|
PIN11 |
COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPES 2 AND 3 IN BRAZIL |
|
Parana R1, Sette H2, Pessoa M3, Crespo D4, Barros F5, Saggia MG6, Santos EA6, Simoes R6 |
|
1Universidade Federal da Bahia, Salvador, BA, Brazil, 2Universidade de São Paulo, Sao Paulo, SP, Brazil, 3Instituto de Infectologia Emílio Ribas, Sao Paulo, SP, Brazil, 4Universidade Federal do Para, Belem, PA, Brazil, 5Universidade Federal de Pernambuco, Recife, PE, Brazil, 6Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PIN12 |
COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN COMPLICATED SKIN AND SOFT-TISSUE INFECTION DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE |
|
De Cock E1, Besnier JM2, Dupon M3, Guéry B4, Levrat F5 |
|
1United BioSource Corporation, Barcelona, Spain, 2CHRU Bretonneau, Bretonneau, France, 3Hôpital Pellegrin, Bordeaux, France, 4Hôpital Calmette, CHRU Lille, Lille, France, 5Pfizer, Paris, France |
| |
|
PIN13 |
COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN NOSOCOMIAL PNEUMONIA DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE |
|
De Cock E1, Timsit JF2, Carlet J3, Leroy O4, Wolff M5, Levrat F6 |
|
1United BioSource Corporation, Barcelona, Spain, 2Hôpital Albert Michallon, Grenoble, France, 3Groupe Hospitalier Paris Saint Joseph, Paris, France, 4Hôpital Guy Chatiliez, Tourcoing, France, 5Hôpital Bichat Claude Bernard, Paris, France, 6Pfizer, Paris, France |
| |
|
PIN14 |
COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA SUSPECTED TO BE CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN SPAIN |
|
León C1, Gómez Mateos JM1, Catalá R2, Vázquez MJ2, Alvarez Rocha L3, Nájera MD4, Rubio-Terrés C5, García M6, Escudero López-Cepero E6 |
|
1Hospital Universitario de Valme, Sevilla, Spain, 2Hospital General de Móstoles, Madrid, Spain, 3Complejo Hospitalario Juan Canalejo, La Coruña, Spain, 4Hospital Universitario Morales Meseguer, Murcia, Spain, 5Health Value, Madrid, Spain, 6Pfizer Spain, Madrid, Spain |
| |
|
PIN15 |
COST-EFFECTIVENESS OF AUGMENTIN ES® FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND |
|
Kawalec P1, Glogowski C2, Cel M2 |
|
1Centrum HTA, Kraków, Poland, 2GSK Commercial Sp. z o.o, Warsaw, Poland |
| |
|
PIN16 |
COST-EFFECTIVENESS OF AUGMENTIN ES® VS AZITHROMYCIN FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND |
|
Kawalec P1, Cel M2, Glogowski C2 |
|
1Centrum HTA, Kraków, Poland, 2GSK Commercial Sp. z o.o, Warsaw, Poland |
| |
|
PIN17 |
ESTIMATING THE LONG-TERM HEALTH AND ECONOMIC IMPACT OF A PROPHYLACTIC CERVICAL CANCER VACCINE ON THE BURDEN OF CERVICAL DISEASE IN ITALY |
|
Ferko N1, Debicki D1, Bamfi F2, Marocco A2, Mantovani LG3 |
|
1i3 Innovus Research Inc, Burlington, ON, Canada, 2GlaxoSmithKline Spa, Verona, Veneto, Italy, 3University of Naples, Federico II, Naples, Italy |
| |
|
PIN18 |
COST-EFFECTIVENESS ANALYSIS OF OSELTAMIVIR FOR INFLUENZA IN JAPAN: MODELING IN THE VIRUS EMERGING RESISTANT TO THE DRUG |
|
Nagase H1, Kamae M2, Moriwaki K3, Yanagisawa S4, Kamae I5 |
|
1Kobe University school of medicine, Kobe, Hyogo-ken, Japan, 2Tufts-NEMC, U.S.A, Boston, MA, USA, 3Kobe University graduate school of medicine, Kobe, Hyogo-ken, Japan, 4Kobe University Graduate School of Medicine, Kobe, Hyogo-ken, Japan, 5Keio University graduate school of health management, Fujisawa, Kanagawa-ken, Japan |
| |
|
PIN19 |
A COST-EFFECTIVENESS ANALYSIS OF A PROPHYLACTIC CERVICAL CANCER VACCINE IN GERMANY: RESULTS FROM A HEALTH ECONOMIC MODEL |
|
Hammerschmidt T1, Siebert U2, Schwarz TF3, Schneider A4, Rogoza RM5, Ferko N6, Welte R1 |
|
1GlaxoSmithKline, Munich, Germany, 2UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i. T, Austria, 3Stiftung Juliusspital, Würzburg, Germany, 4Charité, Berlin, Germany, 5i3 Innovus, Burlington, Ontario, Canada, 6Innovus Research Inc, Burlington, ON, Canada |
| |
|
PIN20 |
COST EFFECTIVENESS ANALYSIS OF BRIVUDINE COMPARED WITH ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN SPAIN |
|
Darba J1, Restovic G2 |
|
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research, Barcelona, Spain |
| |
|
PIN21 |
COST-EFFECTIVENESS OF INFLUENZA VACCINATION FOR HEALTHY ADULTS IN THE NETHERLANDS |
|
Meijboom MJ1, Hak E2, Jansen AG2, Sanders EA3, Buskens E4 |
|
1Pharmerit BV, Rotterdam, The Netherlands, 2Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands, 3Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands, 4University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |
| |
|
PIN22 |
A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF DIRECT AND INDIRECT IMMUNITY CONFERRED BY THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7) |
|
Strutton DR1, Casciano R2, Stern L2, Doyle J2, Berenson K2 |
|
1Wyeth Research, Collegeville, PA, USA, 2Analytica International, New York, NY, USA |
| |
|
PIN23 |
COST-EFFECTIVENESS ANALYSIS OF THE IMPLEMENTATION OF A QUADRIVALENT (6,11,16,18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING BELGIAN CERVICAL CANCER SCREENING PROGRAMME |
|
Annemans L1, Remy V2, Largeron N2 |
|
1Ghent University, Ghent, Belgium, 2Sanofi Pasteur MSD, Lyon, France |
| |
|
PIN24 |
THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE (6,11,16,18) IN NORWAY |
|
Dasbach E1, Elbasha E1, Insinga R1, Nygard J2 |
|
1Merck & Co., Inc., UG1C-60, North Wales, PA, USA, 2Cancer Registry of Norway, Oslo, Norway |
| |
|
PIN25 |
A COST- EFFECTIVENESS STUDY OF A UNIVERSAL VACCINATION PROGRAM WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7) IN SWEDEN |
|
Bergman ASC1, Hjelmgren J1, Wisloff TF2, Kristiansen IS3, Persson U1 |
|
1The Swedish Institute for Health Economics, IHE, Lund, Sweden, 2Norwegian Knowledge Centre for Health Services, Oslo, Norway, 3University of Oslo, Oslo, Norway |
| |
|
PIN26 |
THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN HUNGARY |
|
Dasbach E1, Elbasha E1, Insinga R1, Nagy L2 |
|
1Merck & Co., Inc, North Wales, PA, USA, 2MSD Hungary, Budapest, Hungary |
| |
|
PIN27 |
THE COST-EFFECTIVENESS OF UNIVERSAL INFLUENZA VACCINATION FOR 50-64 YEAR-OLDS IN AUSTRALIA |
|
Harsley SR1, Kelly HA2, MacIntyre R3, Newall AT4, Scuffham PA5 |
|
1CSL Biotherapies, Parkville, Victoria, Australia, 2Victorian Infectious Diseases Reference Laboratory and University of Melbourne, North Melbourne, Victoria, Australia, 3National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, NSW, Australia, 4School of Public Health, The University of Sydney and National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia, 5Griffith University, Meadowbrook, QLD, Australia |
| |
|
PIN28 |
A COST MINIMIZATION ANALYSIS COMPARING DIFFERENT ANTIBIOTIC REGIMENS USED IN TREATING PNEUMONIA IN HONG KONG |
|
Lee KK, Chau MW, Fan BS, Wan MH, Lee VWY |
|
The Chinese University of Hong Kong, Shatin, Hong Kong |
| |
|
PIN29 |
AZITHROMYCIN PLUS CEFTRIAXONE VERSUS LEVOFLOXACIN IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN SPAIN. A COST-MINIMIZATION ANALYSIS |
|
Barberá J1, Martí B2, García M3, Escudero López-Cepero E3 |
|
1Hospital Central de la Defensa Gómez Ulla, Madrid, Madrid, Spain, 2Pfizer, Outcomes Research, Alcobendas, Madrid, Spain, 3Pfizer Spain, Madrid, Spain |
| |
|
PIN30 |
MULTI-CENTRE STUDY ON THE COSTS AND OUTCOMES OF ANTIBIOTIC TREATMENTS IN ITALY FOR COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) |
|
Tarricone R1, Aguzzi G1, Capone A2, Caravaggi CM3, Esposito S4, Franzetti F5, Muzzi A6, Ricci L7, Bassetti M8 |
|
1Bocconi University, Milan, Italy, 2IRCCS Spallanzani, Roma, Italy, 3Abbiategrasso Hospital, Legnano, Italy, 4Gesù and Maria Hospital, Napoli, Italy, 5Luigi Sacco Hospital, Milano, Italy, 6IRCCS Policlinico San Matteo, Pavia, Italy, 7San Donato Hospital, Arezzo, Italy, 8San Martino University Hospital, Genova, Italy |
| |
|
PIN31 |
TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS IN BELGIUM |
|
Akhras K1, Spaepen E2, Merchant S3, Annemans L4 |
|
1Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 2IMS Health, Brussels, BRUSSELS, Belgium, 3Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA, 4Ghent University, Gent, Belgium |
| |
|
PIN32 |
OUTCOMES AND COSTS OF HOSPITAL-ACQUIRED PNEUMONIA ASSOCIATED WITH PSEUDOMONAS OR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A SAMPLE OF BELGIAN HOSPITALS |
|
Merchant S1, Akhras K1, Spaepen E2, Annemans L3 |
|
1Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 2IMS Health, Brussels, Belgium, 3Ghent University, Gent, Belgium |
| |
|
PIN33 |
THE COST OF ZOSTER AND POST-HERPETIC NEURALGIA TREATMENT IN FRANCE |
|
Loock J1, Le Pen C2, Baptiste C3, Bloch K3, Valentin E3, Bruxelle J4, Berrut G5, Gallais JL6, Stahl JP7 |
|
1Aremis Consultants, Neuillly-sur-Seine, France, 2University of Paris-Dauphine, Paris, France, 3Sanofi Pasteur MSD, Lyon, France, 4Tarnier Hospital, Paris, France, 5CHU Angers, Angers, France, 6Société Française de Médecine Générale, Paris, France, 7CHU Grenoble, Grenoble, France |
| |
|
PIN34 |
PREDICTORS OF COSTS FOR SKIN AND SKIN STRUCTURE INFECTIONS DUE TO STAPHYLOCOCCUS AUREUS USING A MANAGED-CARE PERSPECTIVE |
|
Marton JP1, Jackel J2, Carson RT1, Rothermel CD1, Menzin J2 |
|
1Pfizer Inc, New York, NY, USA, 2Boston Health Economics, Inc, Waltham, MA, USA |
| |
|
PIN35 |
MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B: A COST-EFFECTIVENESS ANALYSIS OF ENTECAVIR IN SPAIN |
|
Brosa M1, Buti M2, Staginnus U3, Yuan Y4, Iloeje U5, Zammit D6 |
|
1Oblikue Consulting, Barcelona, Spain, 2Hospital General Universitario Valle de Hebrón, Barcelona, Spain, 3Bristol-Myers Squibb, Madrid, Spain, 4Bristol Myers Squibb, Princeton, NJ, USA, 5Bristol-Myers Squibb, Wallingford, CT, USA, 6Bristol-Myers Squibb, Braine l'Alleud, Belgium |
| |
|
PIN36 |
COST-UTILITY OF PEGINTERFERON-ALFA-2A (40 KD) IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B WITH AND WITHOUT THE “E” ANTIGEN IN BRAZIL |
|
Sette H1, Parana R2, Pessoa M3, Crespo D4, Barros F5, Saggia MG6, Santos EA6, Simoes R6 |
|
1Universidade de São Paulo, Sao Paulo, SP, Brazil, 2Universidade Federal da Bahia, Salvador, BA, Brazil, 3Instituto de Infectologia Emílio Ribas, Sao Paulo, SP, Brazil, 4Universidade Federal do Para, Belem, PA, Brazil, 5Universidade Federal de Pernambuco, Recife, PE, Brazil, 6Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PIN37 |
COST-UTILITY OF ALFAPEGINTERFERON-2A (40 KD) IN CO-INFECTED PATIENTS IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL |
|
Crespo D1, Parana R2, Sette H3, Cheinquer H4, Barros F5, Saggia MG6, Santos EA6, Simoes R6 |
|
1Universidade Federal do Para, Belem, PA, Brazil, 2Universidade Federal da Bahia, Salvador, BA, Brazil, 3Universidade de São Paulo, Sao Paulo, SP, Brazil, 4Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil, 5Universidade Federal de Pernambuco, Recife, PE, Brazil, 6Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PIN38 |
AFFORDABILITY OF ANTIMALARIAL DRUGS IN BENIN CITY, NIGERIA |
|
Udezi WA1, Usifoh CO1, Eze UI2 |
|
1University of Benin, Benin, Edo, Nigeria, 2Olabisi Onabanjo University, Shagamu, Ogun, Nigeria |
| |
|
PIN39 |
ECONOMIC EVALUATION OF A UNIVERSAL CHILDHOOD PNEUMOCOCCAL CONJUGATE VACCINATION STRATEGY IN IRELAND |
|
Tilson L, Usher C, Barry M |
|
National Centre for Pharmacoeconomics, Dublin, Ireland |
| |
|
PIN40 |
AN AUDIT OF HLA-B*5701 SCREENING METHODS AND COSTS IN THE UK |
|
Jackson F1, Thorborn DE2, Maroudas PA1 |
|
1GlaxoSmithKline UK, Uxbridge, UK, 2GlaxoSmithKline Pharma Europe, Brentford, UK |
| |
|
PIN41 |
USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE ECONOMIC BURDEN OF FEBRILE NEUTROPENIA |
|
Durand-Zaleski IS1, Vainchtock A2, Bogillot O3 |
|
1APHP Henri Mondor hospital, Créteil, France, 2HEVA, Lyon, France, 3Amgen, Neuilly sur Seine, France |
| |
|
PIN42 |
EVALUATING THE CLINICAL EFFECTS AND THE COST-EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION WITHIN AN ORGANISED POPULATION-BASED SCREENING SETTING - CASE FINLAND |
|
Torvinen S1, Nieminen P2, Demarteau N3, Bergius S1, Hahl J1 |
|
1GlaxoSmithKline Oy, Espoo, Finland, 2University Central Hospital, Helsinki, Finland, 3IMS HEOR, Brussels, Belgium |
| |
|
PIN43 |
ADAPTATION OF A HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER IN A WELL FUNCTIONING POPULATION-BASED SCREENING SYSTEM - A MODEL CALIBRATION TO FINLAND |
|
Torvinen S1, Nieminen P2, Demarteau N3, Bergius S1, Hahl J1 |
|
1GlaxoSmithKline Oy, Espoo, Finland, 2University Central Hospital, Helsinki, Finland, 3IMS HEOR, Brussels, Belgium |
| |
|
PIN44 |
INCORPORATING PROBABILISTIC ATTRIBUTES IN A STATED-CHOICE RISK-BENEFIT SURVEY |
|
Mohamed AF1, Hauber AB1, Johnson FR1, Watson ME2, Hernandez JE2 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA |
| |
|
PIN45 |
HOW TO IMPROVE THE EXTERNAL VALIDITY AND EXTEND THE EXPIRATION DATE OF ECONOMIC EVALUATIONS |
|
Postma MJ1, Welte R2 |
|
1University of Groningen, Groningen, The Netherlands, 2GSF-National Research Center for Environment and Health, Neuherberg, Germany |
| |
|
PIN46 |
A CROSS-SECTIONAL VALIDATION OF THE MINI-HIV QUESTIONNAIRE |
|
Pedrol E1, Ortega E2, Sanz J3, Suárez-Lozano I4, Perulero N5, García Pulgar MS6, Escayola R6 |
|
1H.Fundación Asilo de Granollers, Barcelona, Spain, 2H.General de Valencia, Valencia, Spain, 3H. Príncipe de Asturias, Alcala de Henares, Madrid, Spain, 4H. Infanta Elena, Huelva, Spain, 5IMS Health, Barcelona, Spain, 6Roche Farma S.A, Madrid, Spain |
| |
|
PIN47 |
DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF THE VACCINEES' PERCEPTION OF INJECTION (VAPI) QUESTIONNAIRE TO ASSESS SUBJECTS' ACCEPTANCE OF INFLUENZA VACCINATION |
|
Chevat C1, Viala M2, Dias C2, Doucet C1, Nguyen VH1 |
|
1Sanofi Pasteur, Lyon, France, 2Mapi Values France, Lyon, France |
METHOD & CONCEPTS
PMC1 |
COMPARISON OF EMR DATA TO US NATIONAL DATA |
| |
Oderda GM1, Brixner D2, Lieberman M3 |
| |
1University of Utah, Salt Lake City, UT, USA, 2The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 3GE Medical Systems, Hillsboro, OR, USA |
| |
|
PMC2 |
A BAYESIAN ADAPTIVE DESIGN FOR EVALUATION OF THE GAP BETWEEN EFFICACY AND ERROR-ADJUSTED EFFECTIVENESS |
|
Moriwaki K1, Kamae I2, Yanagisawa S1, Nagase H3 |
|
1Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 2Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 3Kobe University School of Medicine, Kobe, Hyogo, Japan |
| |
|
PMC3 |
FORMAL OBJECTIVE BAYESIAN METHODS IN COST-EFFECTIVENESS STUDIES |
|
Armero C1, García-Donato G2, López-Quílez A3 |
|
1UNIVERSIDAD DE VALENCIA, Burjassot, Valencia, Spain, 2Universidad de Castilla-La Mancha, Albacete, Albacete, Spain, 3Universidad de Valencia, Burjassot, Valencia, Spain |
| |
|
PMC4 |
PROBABILISTIC SENSITIVITY ANALYSES IN HEALTH ECONOMIC MODELING STUDIES: A QUALITY ASSESSMENT |
|
Getsios D1, Ishak KJ2, Finnegan S3, Caro JJ3, Sullivan SD4, McEwan P5
|
|
1Caro Research Institute, Halifax, NS, Canada, 2Caro Research Institute, Montreal, QC, Canada, 3Caro Research Institute, Concord, MA, USA, 4University of Washington, Seattle, WA, USA, 5Cardiff Research Consortium, Cardiff, Wales, United Kingdom |
| |
|
PMC5 |
USE OF A DIAGNOSIS-BASED RISK ADJUSTMENT MODEL TO ESTIMATE COSTS OF INDIGENT CARE IN A COMMUNITY AT MEDICAID REIMBURSEMENT RATES |
|
Leslie RC1, Shepherd MD1, Simmons SC2 |
|
1University of Texas at Austin, Austin, TX, USA, 2Indigent Care Collaboration, Austin, TX, USA |
| |
|
PMC6 |
THE OPERATIVE INTERVAL OF AN INCREMENTAL COST-EFFECTIVENESS RATIO: A NEW BENCHMARK FOR ASSESSING THE BOUNDARIES ON THE EFFICIENT FRONTIER CURVE |
|
Kamae I1, Moriwaki K2, Yanagisawa S2, Kamae M3 |
|
1Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 2Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 3Tufts-NEMC, U.S.A, Boston, MA, USA |
| |
|
PMC7 |
THE USE OF DISEASE TRANSMISSION MODELLING IN COST-EFFECTIVENESS ANALYSES: STRENGTHS AND WEAKNESSES |
|
Pitman RJ |
|
Oxford Outcomes Ltd, Oxford, Oxfordshire, UK |
| |
|
PMC8 |
THE USE OF ADMNISTRATIVE DATABASE IN ITALY: INSIGHTS FROM THE FRIULI VENEZIA GIULIA CASE |
|
Pitrelli A1, Olivieri D2, Patarnello F1, Frizzo V1, Scudellari F2 |
|
1GlaxoSmithKline spa, Verona, Veneto, Italy, 2University of Verona, Verona, Veneto, Italy |
| |
|
PMC9 |
WITHDRAWN |
|
|
|
|
| |
|
PMC10 |
SPATIAL INTERPOLATION |
|
Van der Steen A, Heeg B, De Charro F, Van Hout BA |
|
Pharmerit Europe, Rotterdam, The Netherlands |
| |
|
PMC11 |
DEALING WITH COMPETING CAUSES OF DEATH, ILLNESS AND COSTS: THE DISEASE ELIMINATION LIFE TABLE ANALYSIS (DELTA) MODEL |
|
Van der Steen A, Verheggen BG, Heeg B, Van Hout BA |
|
Pharmerit Europe, Rotterdam, The Netherlands |
| |
|
PMC12 |
DRUG ADMINISTRATION SERVICES: AN INFUSION STAGE MODEL IN A MULTI-SITE STUDY OF U.S. PHYSICIAN OFFICES |
|
Baker JJ1, Pierce CA2 |
|
1The Resource Group, Pickton, TX, USA, 2The Resource Group, Richfield, OH, USA |
| |
|
PMC13 |
NONLINEAR SMOOTHING TO ASSESS PROBABILITIES OF ANTIBIOTIC-RESISTANT INFECTIONS IN THE COMUNITAT VALENCIANA (SPAIN) |
|
Armero C1, Albert R1, López-Quílez A1, Muñoz I2, Vanaclocha H2 |
|
1Universitat de València, València, Spain, 2Generalitat Valenciana, València, Spain |
| |
|
PMC14 |
ORDINAL OR CARDINAL? THE VAS STRIKES BACK |
|
Chuang LH, Kind P |
|
University of York, York, UK |
| |
|
PMC15 |
CONVERGENT, DISCRIMINANT, CONCURRENT VALIDITY AND RELIABILITY OF THE EQ-5D(CHILD): RESULTS |
|
Scalone L1, Cavrini G2, Broccoli S2, Borghetti F1, Pacelli B3, Matteucci MC2, Tomasetto C2, Selleri P2 |
|
1Center of Pharmacoeconomics, University of Milan, Milan, Italy, 2University of Bologna, Bologna, Italy, 3Health Authority of Bologna, Bologna, Italy |
| |
|
PMC16 |
SF-6D REFERENCE VALUES FOR SPANISH GENERAL POPULATION |
|
Morís J1, Rebollo P2, Alonso J3, Cuervo J2, Zardain PC2, Ferrer M3, Vilagut G3 |
|
1Malaga University and BAP Health Outcomes, Málaga, Spain, 2BAP Health Outcomes Research, Oviedo, Asturias, Spain, 3Institut Municipal d'nvestigació Mèdica, Barcelona, Cataluña, Spain |
| |
|
PMC17 |
ACCOUNTING FOR INITIAL HEALTH STATUS IN MEASURING THE BENEFITS OF HEALTH CARE TECHNOLOGIES |
|
Taylor MJ |
|
University of York, York, UK |
| |
|
PMC18 |
THE ROLE OF CONCEPTUAL MODELS, ENDPOINT MODELS, AND CONCEPTUAL FRAMEWORKS WHEN MAKING TREATMENT BENEFIT CLAIMS TO THE FDA |
|
Wild D1, Donatti C1, Hareendran A2 |
|
1Oxford Outcomes Ltd, Oxford, UK, 2Pfizer, Ltd, Sandwich, UK |
| |
|
PMC19 |
USE OF THE RELIABLE CHANGE INDEX TO EVALUATE CLINICAL SIGNIFICANCE IN HEART TRANSPLANTS |
|
Ortega T1, Valdés C1, Diaz Molina B1, Iscar M1, Ortega F1, Spanish Research Network on Transplantation C2 |
|
1Hospital Universitario Central de Asturias, Oviedo, Spain, 2Spanish Research Network on Transplantation, Madrid, Spain |
| |
|
PMC20 |
UTILITY WEIGHTED COMPARED TO UNWEIGHTED EQ-5D AND HUI3 SUMMARY SCORES: IMPLICATIONS FOR STATISTICAL INFERENCE |
|
Wilke CT1, Pickard AS2, Lee TA3, Walton SM1, Moock J4, Kohlmann T4 |
|
1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Hines VA Hospital and Northwestern University, Chicago, IL, USA, 4University of Greifswald, Greifswald, Germany |
| |
|
PMC21 |
INFLUENCE OF “SOCIAL” AND “SCHOOL” LIFE DIMENSIONS ON CHILDREN'S QUALITY OF LIFE ASSESSED WITH EQ-5D (CHILD) |
|
Matteucci MC1, Tomasetto C1, Selleri P1, Broccoli S1, Borghetti F2, Pacelli B3, Cavrini G1, Scalone L4 |
|
1University of Bologna, Bologna, Italy, 2Center of Pharmacoeconomics, University of Milan, Milan, Italy, 3Health Authority of Bologna, Bologna, Italy, 4Centre of Pharmacoeconomics, Milan, Italy |
| |
|
PMC22 |
THE TURKISH WEIGHTING OF THE EUROQOL |
|
Oksuz E1, Malhan S1, Tulunay FC2 |
|
1Baskent University, Ankara, Turkey, 2Ankara Uuniversity Medical School, Ankara, Turkey |
| |
|
PMC23 |
VALIDITY OF THE SPANISH SF-6D TARIFFS AND EQ-5D COMPARING THE UTILITY VALUES OBTAINED IN FOUR DIFFERENT GROUPS OF PATIENTS |
|
Ruiz MA1, Rejas J2, Pardo A1, Valdés C3, Ortega T3, Soto J2 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain, 3Hospital Universitario Central de Asturias, Oviedo, Spain |
| |
|
PMC24 |
THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE© (SIAQ©): DEVELOPMENT AND CONTENT VALIDATION |
|
Keininger D1, Coteur G2 |
|
1UC
B S.A, Braine-l’Alleud, Belgium, 2SGS Life Sciences, Mechelen, Belgium |
| |
|
PMC25 |
USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH CARE CHARACTERISTICS |
|
Taylor MJ1, Cisse S2 |
|
1University of York, York, UK, 2York Health Economics Consortium, York, UK |
| |
|
PMC26 |
UTILITY INDEX CALCULATION: SIMULATION STUDY CONSIDERING THE HEALTH STATUS AFTER AN INTERVENTION |
|
Morís J1, Rebollo P2, Cuervo J2, Zardain PC2 |
|
1Malaga University and BAP Health Outcomes, Málaga, Spain, 2BAP Health Outcomes Research, Oviedo, Asturias, Spain |
| |
|
PMC27 |
VALIDATION OF THE CAT-HEALTH SYSTEM: THE FIRST COMPUTER-ADAPTIVE TESTING SYSTEM IN SPAIN FOR EVALUATING THE HEALTH RELATED QUALITY OF LIFE OF ILL OR HEALTHY GENERAL POPULATION SUBJECTS |
|
Rebollo P1, García-Cueto E2, Cuervo J1, Zardain PC1, Martínez I1, Muñiz J2 |
|
1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Oviedo University, Oviedo, Spain |
| |
|
PMC28 |
EVALUATING THE EFFECTIVENESS OF SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS |
|
Boler A, Buckley F, Proudfoot C |
|
Heron Evidence Development Ltd, Letchworth, UK |
| |
|
PMC29 |
ESTIMATING THE BUDGET IMPACT OF NEW TECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH BENEFITS IN ISRAEL: STAKEHOLDERS' INCENTIVES FOR ADOPTING A RISK-SHARING MECHANISM |
|
Hammerman A, Greenberg D |
|
Ben-Gurion University of the Negev, Beer-Sheva, Israel |
| |
|
PMC30 |
ECONOMIC ADVANTAGES OF ONLINE DISCRETE EVENT SIMULATION TRAINING |
|
Hunting B, Moller J |
|
Caro Research Institute, Concord, MA, USA |
| |
|
PMC31 |
EVALUATION OF THE PERSPECTIVE AND TYPE OF STUDIES IN ANIMAL HEALTH ECONOMICS |
|
Poulsen Nautrup B1, Poulsen Nautrup C2 |
|
1EAH, Juelich, Northrhine Westf, Germany, 2Ludwig-Maximilians University, Munich, Bavaria, Germany |
| |
|
PMC32 |
U.S. PHYSICIANS: A METHOD TO REPORT QUALITY MEASURES FOR CMS PAY-FOR-PERFORMANCE BONUS COMPENSATION |
|
Pierce CA1, Baker JJ2 |
|
1The Resource Group, Richfield, OH, USA, 2The Resource Group, Pickton, TX, USA |
| |
|
PMC33 |
GUIDELINES FOR ENSURING DEGREES OF VALIDITY IN HEALTH ECONOMIC MODELS |
|
Ray JA1, Ducournau P1, Gyldmark M1, Briggs A2 |
|
1F. Hoffmann - La Roche, Basel, Switzerland, 2University of Glasgow, Glasgow, UK |
| |
|
PMC34 |
BIBLIOGRAPHIC REVIEW OF DISCRETE EVENTS SIMULATION STUDIES IN HEALTH TECHNOLOGY EVALUATION |
|
Monleon T1, Rodriguez-Barrios JM2, Serrano D2 |
|
1University of Barcelona, Barcelona, Spain, 2Medtronic Ibérica SA, Madrid, Spain |
|
|
MUSCULAR-SKELETAL DISORDERS
PMS1 |
DIRECT HEALTH COSTS OF TREATING PATIENTS WITH FIBROMYALGIA IN PRIMARY CARE SETTINGS (PCS) UNDER ROUTINE MEDICAL PRACTICE: A COST OF ILLNESS STUDY USING A CLAIM DATABASE IN SPAIN |
|
Sicras A1, Rejas J2, Navarro R1, Blanca M3, Morcillo A4, Larios R4, Velasco S1, Villarroya C4 |
|
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain, 3Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 4Badalona Serveis Assistencials, Badalona (Barcelona), Spain |
| |
|
PMS2 |
PATIENT-REPORTED-OUTCOMES (PRO) AS A DRIVEN OF DIRECT HEALTH COSTS IN SUBJECTS WITH FIBROMYALGIA: A LONGITUDINAL RETROSPECTIVE PRIMARY CARE SETTINGS (PCS) CLAIM DATABASE ANALYSIS |
|
Sicras A1, Rejas J2, Navarro R3, Blanca M4, Villarroya C5, Velasco S6, Larios R5, Morcillo A5 |
|
1Badalona Serveis Assistencials, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain, 3Badalona Servicios Asistenciales, Barcelona, Spain, 4Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 5Badalona Serveis Assistencials, Badalona (Barcelona), Spain, 6Badalona Serveis Asistencials, Barcelona, Spain |
|
|
OBESITY
|
|
POB1 |
IMPACT OF OBESITY UPON COSTS AND ANTIPSYCHOTIC DRUG USE IN THE ADULT POPULATION SEEN IN SPANISH PRIMARY CARE CENTERS |
|
Sicras-Mainar A1, Rejas-Gutiérrez J2, Navarro-Artieda R3, Blanca-Tamayo M1 |
|
1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain, 3Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain |
| |
|
POB2 |
REDUCING GLOBAL CARDIOMETABOLIC RISK IN OVERWEIGHT OR OBESE INDIVIDUALS WITH DYSLIPIDEMIA: PROJECTED BENEFITS OF RIMONABANT IN A REAL WORLD POPULATION |
|
Getsios D1, Moller J2, McEwan P3, Danel A4, Ishak KJ5, Caro JJ2 |
|
1Caro Research Institute, Halifax, NS, Canada, 2Caro Research Institute, Concord, MA, USA, 3Cardiff Research Consortium, Cardiff, UK, 4Sanofi-Aventis, Paris, France, 5Caro Research Institute, Montreal, QC, Canada |
| |
|
POB3 |
A PROBABILISTIC BAYESIAN MARKOV MODEL IN WINBUGS FOR THE ECONOMIC EVALUATION OF THE TREATMENT WITH ORLISTAT OF ITALIAN OBESE PATIENTS |
| |
Iannazzo S, Pradelli L |
| |
Advanced Research Srl, Turin, Italy |
| |
|
POB4 |
GEMCAS MODEL - A DECISION ANALYTIC MODEL ASSESSING THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESITY AND ASSOCIATED CARDIOVASCULAR RISK FACTORS |
|
Aidelsburger P1, Fuchs SM1, Hessel F2, Ulle T1, Wasem J3 |
|
1CAREM GmbH, Sauerlach, Germany, 2Sanofi-Aventis, Berlin, Germany, 3University of Duisburg-Essen, Essen, Germany |
| |
|
POB5 |
QUANTIFYING THE QUALITY OF ECONOMIC EVALUATIONS OF OBESITY INTERVENTIONS: A CRITICAL APPRAISAL OF THE LITERATURE |
|
Redekop WK1, Kortram Z2 |
|
1Erasmus Medical Center, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands |
|
|
PAIN
PPN1 |
INCIDENCE OF ACUTE PAIN IN TURKEY |
|
Tulunay FC1, Malhan S2 |
|
1Ankara University Medical School, Ankara, Turkey, 2Baskent University, Faculty of Health Sciences, Ankara, Turkey |
| |
|
PPN2 |
A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN |
|
Wallerstein KRB |
|
Pharma Focus, Belle Mead, NJ, USA |
| |
|
PPN3 |
EXPECTED COST AND COST CONSIDERATIONS ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC NON-CANCER PAIN: A SIMULATION MODEL |
|
Magar RS1, Fine PG2, White RE3 |
|
1PPD, Morrisville, NC, USA, 2University of Utah - Pain Research Center, Salt Lake City, UT, USA, 3Endo Pharmaceuticals, Chadds Ford, PA, USA |
| |
|
PPN4 |
HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN |
|
Saldaña MT1, Navarro A2, Pérez C3, Torrades S4, Rejas J5 |
|
1Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 2Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 3Hospital University La Princesa, Madrid, Spain, 4European Biometric Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
PPN5 |
LONGITUDINAL HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS): A 12-WEEKS POST-HOC ANALYSIS OF THE PREGABALIN EFFECT UNDER ROUTINE MEDICAL PRACTICE |
|
Pérez C1, Navarro A2, Saldaña MT3, Masramon X4, Rejas J5 |
|
1Hospital University La Princesa, Madrid, Spain, 2Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 3Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 4European Biometrics Institute, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
PPN6 |
HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PERIPHERAL NEUROPATHIC PAIN (NEP) IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN |
|
Navarro A1, Saldaña MT2, Pérez C3, Masramon X4, Rejas J5 |
|
1Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 2Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 3Hospital University La Princesa, Madrid, Spain, 4European Biometrics Institute, Barcelona, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain |
| |
|
PPN7 |
RESOURCE UTILIZATION DUE TO BREAKTHROUGH PAIN: RESULTS FROM A PROSPECTIVE STUDY ON PATIENTS WITH CHRONIC PAINFUL CONDITIONS |
|
Pizzi LT1, Lee SP1, Richardson D1, Cobb N2, Leas B2, Toner R2, Pracilio V2, Ballas S2, Ashkenazi A2, Derk CT2, Wang D2, DeSousa E2 |
|
1Jefferson Medical College, Philadelphia, PA, USA, 2The Breakthrough Pain Study Group, Philadelphia, PA, USA |
| |
|
PPN8 |
CHRONIC PAIN TREATMENT WITH OPIOIDS: PRACTICE DOES NOT FOLLOW POLICY |
|
Victor TW, Alvarez NA, Gould EM |
|
Endo Pharmaceuticals Inc, Chadds Ford, PA, USA |
| |
|
PPN9 |
PERCEPTION OF BREAKTHROUGH PAIN IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS |
|
Pizzi LT1, Lee SP1, Richardson D1, Cobb N2, Leas B2, Toner R2, Pracilio V2, Ballas S2, Ashkenazi A2, Derk CT2, Wang D2, DeSousa E2 |
|
1Jefferson Medical College, Philadelphia, PA, USA, 2The Breakthrough Pain Study Group, Philadelphia, PA, USA |
| |
|
PPN10 |
LINGUISTIC ADAPTATION INTO SPANISH AND PSYCHOMETRIC VALIDATION OF THE NEUROPATHIC PAIN SCREENING QUESTIONNAIRE: ID PAIN. |
|
Gálvez R1, Pardo A2, Cerón JM3, Villasante F4, Aranguren JL5, Saldaña MT6, Navarro A7, Ruiz MA2, Díaz S8, Rejas J9 |
|
1University Hospital “Virgen de las Nieves”, Granada, Spain, 2Universidad Autónoma de Madrid, Madrid, Spain, 3Primary Care Centre “San Antonio”, Motril, Granada, Spain, 4Primary Care Centre “José Marvá”, Madrid, Spain, 5Clínica MADRID, Fuenlabrada, Madrid, Spain, 6Primary Care Centre “Raíces”, Castrillón, Asturias, Spain, 7Primary Care Centre “Puerta del Ángel”, Madrid, Spain, 8Euroclin Institute, Madrid, Spain, 9Pfizer Spain, Madrid, Spain |
| |
|
PPN11 |
ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH SEVERE CHRONIC PAIN |
|
Lloyd A1, Meguro M1, Dewilde S2, MacLaine G3, Verdian L3 |
|
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Brussels, Belgium, 3Eisai Europe Limited, Hatfield, Herthfordshire, UK |
| |
|
PPN12 |
TURKISH MCGILL PAIN QUESTIONNAIRE: RELIABILITY AND VALIDATION |
|
Oksuz E1, Malhan S1, Tulunay FC2 |
|
1Baskent University, Ankara, Turkey, 2Ankara Uuniversity Medical School, Ankara, Turkey |
|
|
SKIN
PSK1 |
IMPACT OF SECONDARY PROPHYLACTIC USE OF TACROLIMUS 0.1% OINTMENT ON QUALITY-OF-LIFE, TREATMENT OUTCOMES AND COSTS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS |
|
Wollenberg A1, Sidhu M2, Odeyemi IA2, Dorsch B3, Köhne-Volland R3, Schaff M4, Ehlken B4, Berger K4 |
|
1Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians Universität, München, Germany, 2Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3Metronomia Clinical Research GmbH, München, Germany, 4MERG - Medical Economics Research Group, München, Germany |
| |
|
PSK2 |
PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM SYSTEMIC PSORIASIS-THERAPY: PATIENT REGISTRY OF HEALTH SERVICES IN GERMANY |
|
Rustenbach SJ, Schäfer IA, Radke M, Augustin M |
|
University Clinics of Hamburg, Hamburg, Germany |
| |
|
PSK3 |
WITHDRAWN |
| |
|
PSK4 |
COST COMPARISON BETWEEN TWO ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPIES IN PATIENTS WITH PSORIASIS USING AVERAGE SALES PRICE |
|
Tang B, Rahman MI, Thompson HC, Hilliard R, Naim A, Dabbous O |
|
Centocor, Inc, Horsham, PA, USA |
| |
|
PSK5 |
MANAGEMENT AND COST OF GENITAL WARTS IN ITALY |
|
Merito M1, Largeron N2, Trichard M2, Cohet C2, Boselli F3, Mateeli A4, Naldi L5, Vittori G6 |
|
1Informa S.r.l, Rome, Italy, 2sanofi pasteur MSD, Lyon, France, 3University of Modena and Reggio Emilia, Modena, Italy, 4University of Brescia, Brescia, Italy, 5CentroStudi GISED, Bergamo, Italy, 6Clinica Ginecologica, Rome, Italy |
| |
|
PSK6 |
IMPACT OF PSORIASIS DISEASE ON ANNUAL TOTAL HEALTHCARE COSTS AND RESOURCE UTILIZATION AMONG MEDICAID RECIPIENTS |
|
Dabbous O1, Naim A1, Chalissery G2, Tang B1, Rahman MI1 |
|
1Centocor, Inc, Horsham, PA, USA, 2Hmetrix, Bala Cynwyd, PA, USA |
| |
|
PSK7 |
EVALUATION OF THE ASSOCIATION BETWEEN PSORIASIS SEVERITY AND HOSPITAL RESOURCE USE IN THE UK |
|
Currie CJ1, Conway P2 |
|
1Cardiff University, Cardiff, UK, 2Wyeth Europa, Berkshire, UK |
| |
|
PSK8 |
ASSESSMENT OF INVOLVED BODY SURFACE AREA (BSA) IN PSORIASIS PATIENTS. VALIDATION OF SOFTWARE ASSISTED DIAGNOSIS BSA FOR THE MANAGEMENT OF PSORIASIS |
|
Espallardo O1, Badia X2, Bermudez L1, Perulero N2, Aragües M3, Bordas X4, Costa J5, Dauden E3, Filipe P5, Ginarte M6, Jimenez R7, Pereiro M6, Perez A8, Sanchez JL8, Servitje O4, Vélez A7 |
|
1Merck Serono, Spain, Madrid, Spain, 2IHMS Health, Barcelona, Spain, 3Hospital La Princesa, Madrid, Spain, 4Hospital de Bellvitge, Madrid, Spain, 5Hospital Santa Maria, Madrid, Portugal, 6Hospital Gil Casares, Madrid, Spain, 7Hospital Reina Sofía, Madrid, Spain, 8Hospital General de Valencia, Madrid, Spain |
| |
|
PSK9 |
PRIOR AUTHORIZATION FOR TOPICAL PSORIASIS TREATMENTS: IS IT COST-BENEFICIAL FOR MANAGED CARE? |
|
Balkrishnan R1, Bhosle MJ1, Joish VN2, Feldman SR3 |
|
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA |
| |
|
PSK10 |
QUANTITATIVE ASSESSMENT OF PATIENT-DEFINED BENEFIT IN DERMATOLOGY |
|
Schaefer I, Rustenbach S, Reich C, Augustin M |
|
University Clinics of Hamburg, Hamburg, Germany |
| |
|
PSK11 |
EVALUATION OF THE ASSOCIATION BETWEEN EQ5D UTILITY AND DERMATOLOGY LIFE QUALITY INDEX (DLQI) SCORE IN PATIENTS WITH PSORIASIS |
|
Currie CJ1, Conway P2 |
|
1Cardiff University, Cardiff, UK, 2Wyeth Europa, Berkshire, UK |
| |
|
PSK12 |
PATIENT REPORTED OUTCOMES IN PSORIASIS |
|
Garcia-Diez A1, Ferrandiz C2, Bermudez-Rey L3, Espallardo O4, Lizan L5, Badia X5 |
|
1Hospital Universitario La Princesa, Madrid, Spain, 2Hospital Germans Trias i Pujol, Badalona, Spain, 3Serono, Madrid, Spain, 4Merck Serono, Spain, Madrid, Madrid, Spain, 5IMS Health, Barcelona, Spain |
| |
|
PSK13 |
PSYCHOMETRIC VALIDATION OF THE OILY SKIN SELF ASSESSMENT SCALE (OSSAS) AND THE OILY SKIN IMPACT SCALE (OSIS) |
|
Arbuckle R1, Clark M2, Scott J3, Harness J4, Bonner N1, Draelos Z5, Rizer R6 |
|
1Mapi Values Ltd, Bollington, Cheshire, UK, 2Pfizer Inc, Ann Arbor, MI, USA, 3Mapi Values Ltd, Boston, MA, USA, 4Pfizer Global R&D, Ann Arbor, MI, USA, 5Wake Forest University School of Medicine, High Point, NC, USA, 6Thomas J Stephens & Associates Inc, Colorado Springs, CO, USA |
SMOKING
PSM1 |
COST-EFFECTIVENESS ANALYSIS OF CHAMPIX® (VARENICLINE)
IN SMOKING CESSATION TREATMENT IN SPAIN |
|
F Bobadilla J1, Brosa M2, Wilson K3, Sánchez Maestre C4 |
|
1Pfizer Spain, Madrid, Spain, 2Oblikue Consulting, Barcelona, SC, Spain, 3Pfizer European Brand Team, Surrey, UK, 4Pfizer Spain, Madrid, Madrid, Spain |
| |
|
PSM2 |
A COST- EFFECTIVENESS ANALYSIS OF A COMMUNITY PHARMACIST BASED SMOKING CESSATION PROGRAM IN THAILAND |
|
Thavorn K, Chaiyakunapruk N, Nimpitakpong P |
|
Naresuan University, Phitsanulok, Thailand |
| |
|
PSM3 |
AN EVALUATION OF THE COST-EFFECTIVENESS OF AN EXTENDED COURSE OF VARENICLINE IN PREVENTING SMOKERS WHO HAVE QUIT FROM RELAPSING |
|
Knight CJ1, Howard PA1, Baker CL2 |
|
1Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK, 2Pfizer Inc, New York, NY, USA |
| |
|
PSM4 |
HEALTH ECONOMIC MODEL OF SMOKING CESSATION TREATMENT WITH VARENICLINE IN GERMANY |
|
Rasch A1, Lenz C2, Greiner W1 |
|
1University of Bielefeld, Bielefeld, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
PSM5 |
USE OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ) AND THE ENVIRONMENTAL TOBACCO SMOKE QUESTIONNAIRE (ETS-Q) IN AN INTERNATIONAL STUDY |
|
Petitjean C1, Christensen T2 |
|
1Mapi Research Institute, Lyon, Rhone, France, 2Novo Nordisk A/S, Bagsværd, Denmark |
| |
|
PSM6 |
REAL WORLD USAGE PATTERNS OF OVER-THE-COUNTER NICOTINE PATCHES |
|
Shi CW, Ganiats T |
|
UC San Diego, La Jolla, CA, USA |
|
|
SURGERY
PSU1 |
COST-EFFECTIVENESS OF STAPLED HAEMORRHOIDOPEXY (PPH) COMPARED WITH MILLIGAN-MORGAN TECHNIQUE MM IN PATIENTS IN WHOM SURGICAL INTERVENTION IS CONSIDERED APPROPRIATE FOR THE TREATMENT OF PROLAPSED INTERNAL HAEMORRHOIDS IN UK |
|
Griffin A1, Rupprech F2, Ribaric G2, Morlotti L2 |
|
1Johnson & Johnson, Bucks, UK, 2Ethicon Endo Surgery, Norderstedt, Germany |
| |
|
PSU2/ES4 |
THE RELATIVE COST-EFFECTIVENESS OF THE FENTANYL HCL PATIENT-ACTIVATED TRANSDERMAL SYSTEM (ITS) IN ACUTE POST-OPERATIVE PAIN MANAGEMENT (POPM) IN GREECE |
|
Yfantopoulos I1, Papanicolaou S2, Papagianopoulou V1, Van Bellinghen LA3, Annemans L4
|
|
1University of Athens, Athens, Greece, 2Janssen-Cilag Pharmaceutical SACI, Athens, Greece, 3IMS HEOR, Brussels, Belgium, 4Ghent University, Ghent, Belgium |
| |
|
PSU3 |
THE EFFECTS OF LAPAROSCOPIC SURGERY AND NOSOCOMIAL INFECTIONS ON THE COST OF CARE: EVIDENCE FROM THREE SURGICAL PROCEDURES |
|
Rizzo J1, Gunnarsson C2, Hochheiser L3, Moore M4 |
|
1Stony Brook University, Stony Brook, NY, USA, 2S2 Statistical Solutions, Inc, Cincinnati, OH, USA, 3Humana, Inc, Jackson, WY, USA, 4Ethicon Endo-Surgery, Inc, Cincinnati, OH, USA |
| |
|
PSU4 |
RETROSPECTIVE STUDY OF COMPLICATIONS AND RESOURCE USE IN ENDOVASCULAR MANAGEMENT OF AAA |
|
Muszbek N1, Van Sambeek MR2, Soong CV3, Thompson MM4, Gavriel S1, Hutton J5, Brasseur P6 |
|
1United BioSource Corporation, London, UK, 2Erasmus University Medical Center, Rotterdam, The Netherlands, 3Belfast City Hospital, Belfast, UK, 4St George’s Hospital NHS Trust, London, UK, 5University of York, York, UK, 6Medtronic International SA, Tolochenaz, Switzerland |
| |
|
PSU5 |
SYSTEMATIC REVIEW OF PATIENT REPORTED OUTCOMES FOLLOWING INTRADISCAL ELECTROTHERMAL THERAPY (IDET) OR SPINAL FUSION FOR DISCOGENIC LOW BACK PAIN |
|
Andersson GB1, Mekhail NA2, Block JE3 |
|
1Rush Medical College, Chicago, IL, USA, 2Cleveland Clinic Foundation, Cleveland, OH, USA, 3Jon E Block PhD Inc, San Francisco, CA, USA |
10th Annual European Congress Main Page |
|